ClinicalTrials.gg
CompletedNCT04394351EoE KIDSUpdated Oct 27, 2025Results posted

Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)

A Phase 3 interventional study of Dupilumab and Matching Placebo in Eosinophilic Esophagitis (EoE), sponsored by Regeneron Pharmaceuticals. Completed at 27 sites in 2 countries. Open to participants aged 1 Year to 11 Years. Per ClinicalTrials.gov, last updated 2025-10-27.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
1 Year to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing dupilumab in Eosinophilic Esophagitis — 4 open to participants now, 7 under way, 1 of them phase 3. dupilumab · Eosinophilic Esophagitis.

Enrollment
2nd of 11
102 · median 47
Started
2020
the only one that year
Phase 3
3 of 11
1 open now
Registered
3rd of 11
by date
Lead sponsor
5 of 11
Regeneron Pharmaceuticals

Among the 11 studies testing dupilumab in Eosinophilic Esophagitis, this one is the 2nd largest by enrollment, is the only one that started in 2020, is one of 3 in phase 3, and was the 3rd registered.

Eosinophilic Esophagitis

235 studies on the registry are indexed under Eosinophilic Esophagitis; 53 are open to participants now.

Browse Eosinophilic Esophagitis studies →

Open to participants now

4 of the 11 studies testing dupilumab in Eosinophilic Esophagitis are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 42 Eosinophilic Esophagitis studies recruiting now, 12 (29%) set no upper age limit and 27 (64%) stop at 75 or younger; 27 take children under 18; 7 take healthy volunteers.

This study: 1 Year to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing dupilumab in Eosinophilic Esophagitis, or all of them as a file.
02

Study summary

The Primary objective is to demonstrate the efficacy of dupilumab treatment compared with placebo in pediatric patients with active eosinophilic esophagitis (EoE) based on histologic improvement meeting validated histologic criteria.

The Secondary objectives are:

  • To demonstrate the efficacy of dupilumab compared to placebo in pediatric patients with active EoE after 16 weeks of treatment as assessed by endoscopic visual measurements of disease activity using the Eosinophilic Esophagitis-Endoscopic Reference Score (EoE-EREFS) and histologic abnormalities as measured by the EoE Histology Scoring System (EoE-HSS)
  • To evaluate the safety, tolerability, and immunogenicity of dupilumab treatment for up to 16 weeks in pediatric patients with active EoE
  • To evaluate the effects of dupilumab on transcriptomic signatures associated with EoE and type 2 inflammation
  • To study the effects of dupilumab on the type 2 inflammation gene expression signature
  • To evaluate the concentration-time profile of functional dupilumab in serum in this population
  • To assess efficacy of long-term (up to 160 weeks) dupilumab treatment
  • To assess the impact of dupilumab treatment on changes in weight and growth during the extended active period and open-label extension period of the study
  • To assess safety, tolerability, and immunogenicity of long-term (up to 160 weeks) dupilumab treatment
  • To evaluate the impact of dupilumab treatment on EoE signs and symptoms
Read the detailed description

This is a 3-part study:

  • Part A: Double-blind 16-week treatment period
  • Part B: 36-week extended active treatment period
  • Part C: Up to108 weeks open-label extension period
03

Conditions studied

  • Eosinophilic Esophagitis (EoE)
04

Who can participate

Ages eligible
1 Year to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. A documented diagnosis of eosinophilic esophagitis (EoE)
  2. Baseline endoscopic with a demonstration on central reading of intraepithelial eosinophilic infiltration

Key Exclusion Criteria:

  1. Body weight \<5 kg or ≥60 kg at screening
  2. Other causes of esophageal eosinophilia
  3. Active Helicobacter pylori
  4. History of Crohn's disease, ulcerative colitis, celiac disease, or prior esophageal surgery
  5. Any esophageal stricture unable to be passed with a standard, diagnostic, upper endoscope or any critical esophageal stricture that requires dilation at screening
  6. Treatment with swallowed topical within 8 weeks prior to baseline standard of care endoscopy
  7. History of bleeding disorders or esophageal varices that, in the opinion of the investigator, would put the patient at undue risk for significant complications from an endoscopy procedure
  8. Active parasitic infection or suspected parasitic infection
  9. Known or suspected immunodeficiency disorder

Key Exclusion for Patients Re-Entering the Study (for Entry into Part C, as defined in protocol):

  1. Patients who are ≥12 years old, weigh ≥40 kg (or minimum weight for which dupilumab is approved for EoE), and dupilumab is commercially available for the treatment of EoE in their country
  2. Patients who, during their previous participation in this clinical trial, developed an SAE and/or AE deemed related to dupilumab, which in the opinion of the investigator or of the medical monitor could indicate that continued treatment with dupilumab may present an unreasonable risk for the patient
  3. Patients who did not undergo endoscopy with biopsies at week 16 and/or week 52 or prior to receiving rescue treatment Note: If the endoscopy with biopsies could not occur due to COVID-19 restrictions and rescue treatment was needed to be initiated without delay, these patients will be eligible to participate in Part C
  4. Patients who became pregnant during their previous participation in this dupilumab clinical trial
  5. Patients who, during their previous participation in this trial, were prematurely withdrawn because of a protocol violation, poor compliance, or inability to complete required study assessments

NOTE: Other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Part A - High Dose

    Part A consists of a 16-week double-blind treatment period. Patients will be randomized to receive dupilumab or placebo subcutaneous (SC) administration at tiered dosing regimens based on body weight

    Drug: Dupilumab · Drug: Matching Placebo

  • Experimental
    Part A - Low Dose

    Part A consists of a 16-week double-blind treatment period. Patients will be randomized to receive dupilumab or placebo subcutaneous (SC) administration at tiered dosing regimens based on body weight

    Drug: Dupilumab · Drug: Matching Placebo

  • Experimental
    Part B - High Dose

    Part B consists of a 36-week extended active treatment period. All patients to receive subcutaneous (SC) administration at tiered dosing regimens based on body weight

    Drug: Dupilumab · Drug: Matching Placebo

  • Experimental
    Part B - Low Dose

    Part B consists of a 36-week extended active treatment period. All patients to receive subcutaneous (SC) administration at tiered dosing regimens based on body weight

    Drug: Dupilumab · Drug: Matching Placebo

  • Experimental
    Part C - High Dose

    Part C consists of up to 108-week open-label extension period. All patients will receive higher exposure dupilumab subcutaneous (SC) administration at tiered dosing regimens based on body weight. No matching placebo administered in Part C.

    Drug: Dupilumab

Interventions

  • Single-use, prefilled syringe

    Also known as: •DUPIXENT, •REGN668, •SAR231893

  • DrugMatching Placebo

    Matching formulation and regimen (depending on the weight tier) as dupilumab without the active substance

06

What researchers measure

Primary outcomes

  1. Part A: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of Less Than or Equal to (≤) 6 Eosinophils/High Power Field (Eos/Hpf) at Week 16

    Peak esophageal intraepithelial eosinophil count was measured from esophageal biopsies. A total of at least 9 mucosal pinch biopsies were collected from 3 esophageal regions: 3 proximal, 3 mid, and 3 distal. The peak esophageal intraepithelial eosinophil count at each visit was the maximum of the quantities of eosinophils in the most inflamed hpfs across the 3 regions. If the quantity of eosinophils was missing for 1 or 2 esophageal regions, the peak eosinophil count was the maximum of the quantities of eosinophils from the region(s) where eosinophil quantities were available.

    Time frame: At Week 16

Secondary outcomes

  1. Part A: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eosinophils/High Power Field at Week 16

    Peak esophageal intraepithelial eosinophil count was measured from esophageal biopsies. A total of at least 9 mucosal pinch biopsies were collected from 3 esophageal regions: 3 proximal, 3 mid, and 3 distal. The peak esophageal intraepithelial eosinophil count at each visit was the maximum of the quantities of eosinophils in the most inflamed hpfs across the 3 regions. If the quantity of eosinophils was missing for 1 or 2 esophageal regions, the peak eosinophil count was the maximum of the quantities of eosinophils from the region(s) where eosinophil quantities were available.

    Time frame: At Week 16

  2. Part A: Percent Change From Baseline in Peak Esophageal Intraepithelial Eosinophil Count at Week 16

    Peak esophageal intraepithelial eosinophil count was measured from esophageal biopsies. A total of at least 9 mucosal pinch biopsies were collected from 3 esophageal regions: 3 proximal, 3 mid, and 3 distal. The peak esophageal intraepithelial eosinophil count at each visit was the maximum of the quantities of eosinophils in the most inflamed hpfs across the 3 regions. If the quantity of eosinophils was missing for 1 or 2 esophageal regions, the peak eosinophil count was the maximum of the quantities of eosinophils from the region(s) where eosinophil quantities were available. Least squared (LS) mean and standard error (SE) from analysis of covariance (ANCOVA) model with Baseline measurement as covariate and the treatment, baseline weight group strata as fixed factors.

    Time frame: Baseline, Week 16

  3. Part A: Change From Baseline in Mean Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) Grade Score at Week 16

    EoE-HSS is a validated histologic scoring system that measures other histological abnormalities in addition to density of eosinophilic infiltration. Severity (grade) and extent (stage) of abnormalities will be scored using a 4-point scale (0 normal; 3 maximum change). Higher total score indicated greater severity \& extent of histological abnormalities. For each of 3 esophageal regions (proximal, mid, and distal), the ratio of the sum of assigned score for each evaluated feature divided by maximum possible score (maximum value is 24) was calculated. The mean grade scores summed over the 3 regions was the final score used in primary analysis, the mean grade score ranged from 0 to 3, with higher score indicating more severe.

    Time frame: Baseline, Week 16

  4. Part A: Change From Baseline in Mean Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) Stage Score at Week 16

    EoE-HSS is a validated histologic scoring system that measures other histological abnormalities in addition to density of eosinophilic infiltration. Severity (grade) and extent (stage) of abnormalities will be scored using a 4-point scale (0 normal; 3 maximum change). Higher total score indicated greater severity \& extent of histological abnormalities. For each of 3 esophageal regions (proximal, mid, and distal), the ratio of the sum of assigned score for each evaluated feature divided by maximum possible score (maximum value is 24) was calculated. The mean stage scores summed over the 3 regions was the final score used in primary analysis, the mean stage score ranged from 0 to 3, with higher score indicating more severe.

    Time frame: Baseline, Week 16

  5. Part A: Normalized Enrichment Score (NES) for the Relative Change From Baseline in the Type 2 Inflammation Signature (T2INF) at Week 16

    A Normalized Enrichment Score (NES) is a way to generate a single numerical value to represent a complex gene expression signature. Changes in NES score represented the overall changes in the expression of that molecular phenotype. The NESs calculated for T2INF reflect the expression at Week 16 relative to Baseline of the pre-specified gene set as a way to evaluate normalization of type 2 inflammation with treatment. For each subject, an NES of 0 indicates no change from baseline, a negative score shows a reduction in disease score (more like normal) and positive score shows worsening (more active disease). NES does not have a minimum/maximum score.

    Time frame: Baseline, Week 16

  6. Part A: Normalized Enrichment Score (NES) for the Relative Change From Baseline in the Eosinophilic Esophagitis (EoE) Diagnostic Panel (EDP) at Week 16

    A Normalized Enrichment Score (NES) is a way to generate a single numerical value to represent a complex gene expression signature. Changes in NES score represented the overall changes in the expression of that molecular phenotype. The NESs calculated for the EDP reflect the expression at Week 16 relative to Baseline of a gene set that is differentially expressed between esophageal biopsies from EoE participants compared to healthy controls as a way to evaluate normalization of the molecular pathology. For each subject, an NES of 0 indicates no change from baseline, a negative score shows a reduction in disease score (more like normal) and positive score shows worsening (more active disease). NES does not have minimum/maximum score.

    Time frame: Baseline, Week 16

  7. Part A: Absolute Change From Baseline in EoE Endoscopic Reference Total Score (EoE-EREFS) at Week 16

    The EoE-EREFS is a validated endoscopic scoring system for inflammatory and remodeling features of EoE including edema, rings, exudates, furrows, and stricture. The score was assessed in the proximal and distal esophageal regions with each region scored from 0 to 9 with total scores ranging from 0 to 18. Higher scores indicate worse endoscopic inflammatory and remodeling findings.

    Time frame: Baseline, Week 16

  8. Part A: Change From Baseline in the Proportion of Days With 1 or More EoE Signs as Measured by Pediatric EoE Sign/Symptom Questionnaire - Caregiver Version (PESQ-C) at Week 16 (for Participants Aged ≥1 to <12 Years)

    PESQ-C is a novel, observer-reported outcome measure intended to be completed independently by caregivers of all pediatric EoE participants in the study. PESQ-C measures the signs of EoE observed by the caregiver, including stomach pain, heartburn, acid reflux, regurgitation, vomiting, food refusal, and trouble swallowing food. Data from a 14-day period preceding the baseline visit and a 14-day period preceding week 16 will be used to calculate the proportion of days with 1 or more EoE symptoms.

    Time frame: Baseline, Week 16

  9. Part A: Number of Sign-free Days During the 14-day Period Preceding Week 16 as Measured by the PESQ-C (for Participants Aged ≥1 to <12 Years)

    PESQ-C is a novel, observer-reported outcome measure intended to be completed independently by caregivers of all pediatric EoE participants in the study. The PESQ-C measures the signs of EoE observed by the caregiver, including stomach pain, heartburn, acid reflux, regurgitation, vomiting, food refusal, and trouble swallowing food. WOCF approach was used for imputing the missing data due to rescue treatment/AE/lack of efficacy, and the multiple imputations approach was used for the missing data due to other reasons. LS mean SE derived from ANCOVA model.

    Time frame: Week 16

  10. Part A: Change From Baseline in the Proportion of Total Segments Within a Day (Night, Morning, Afternoon, Evening) With 1 or More EoE Signs as Measured by the PESQ-C at Week 16

    PESQ-C is a novel, observer-reported outcome measure intended to be completed independently by caregivers of all pediatric EoE participants in the study. The PESQ-C measured the occurrence of signs of EoE and was completed once daily via an electronic diary. Data from a 14-day period preceding the baseline visit and a 14-day period preceding week 16 will be used to calculate the total time segments within a day (night, morning, afternoon, evening) with 1 or more EoE symptoms.

    Time frame: Baseline, Week 16

  11. Part A: Change From Baseline in the Proportion of Days With 1 or More EoE Signs by Pediatric EoE Sign/Symptom Questionnaire - Participant Version (PESQ-P) (for Participants Aged ≥8 to <12 Years) at Week 16

    The PESQ-P was a participant-reported outcome measure intended to be completed independently by participants ≥8 to \<12 years of age. The PESQ-P measured occurrence of signs of EoE and was completed once daily via an electronic diary. Data from a 14-day period preceding the baseline visit and a 14-day period preceding week 16 will be used to calculate the proportion of days with 1 or more EoE symptoms.

    Time frame: Baseline, Week 16

  12. Part A: Number of Symptom-free Days During the 14-day Period Preceding Week 16 as Measured by the PESQ-P (for Participants Aged ≥8 to <12 Years)

    The PESQ-P was a participant-reported outcome measure intended to be completed independently by EoE participants ≥8 to \<12 years of age. The PESQ-P measures the signs of EoE, including stomach pain, heartburn, acid reflux, regurgitation, vomiting, food refusal, and trouble swallowing food. The PESQ-P score was calculated based on the daily responses over a 14-day period (i.e., the 14 days prior to the baseline visit and the week 16 visit). The score ranges from 0 to 1. WOCF approach was used for imputing the missing data due to rescue treatment/AE/lack of efficacy, and the multiple imputations approach was used for the missing data due to other reasons. LS Mean SE from ANCOVA.

    Time frame: Week 16

  13. Part A: Change From Baseline in the Proportion of Total Segments Within a Day (Night, Morning, Afternoon, Evening) With 1 or More EoE Signs as Measured by the PESQ-P (for Participants Aged ≥8 to <12 Years) at Week 16

    The PESQ-P was a participant-reported outcome measure intended to be completed independently by EoE participants ≥8 to \<12 years of age. The PESQ-P measured the occurrence of signs of EoE and was completed once daily via an electronic diary. Data from a 14-day period preceding the baseline visit and a 14-day period preceding week 16 will be used to calculate the total time segments within a day (night, morning, afternoon, evening) with 1 or more EoE symptoms.

    Time frame: Baseline, Week 16

  14. Part A: Change From Baseline in Total Score as Measured by the Pediatric Eosinophilic Esophagitis Symptom Score (PEESS) Version 2.0 Caregiver Version (PEESSv2.0-C) at Week 16

    The PEESSv2.0-C is a caregiver-reported outcome measure that assesses the frequency and severity of EoE symptoms among pediatric participants. The PEESSv2.0-C consists of 20 items and has a one-month recall period. Each item had a 0-4 scale, which was transformed to 0-100 as follows: 0 = 0, 1 = 25, 2 = 50, 3 = 75, 4 = 100. The mean total PEESSv2.0 score was computed as the sum of all the item scores over the number of items answered. The total PEESSv2.0-C score ranges from 0 to 100 where higher scores indicate greater symptom burden among pediatric EoE participants. Values after first rescue treatment use were set to missing (censoring). WOCF approach was used for imputing the missing data due to rescue treatment/AE/lack of efficacy, and the MI approach was used for the missing data due to other reasons. LS mean SE from ANCOVA model.

    Time frame: Baseline, Week 16

  15. Part A: Concentration of Functional Dupilumab in Serum at Baseline, Week 4 and 16

    Concentration of functional dupilumab in serum at Baseline, Week 4 and 16 was reported in this outcome measure.

    Time frame: Baseline, Week 4 and 16

  16. Part B: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eosinophils/High Power Field at Week 52

    Peak esophageal intraepithelial eosinophil count was measured from esophageal biopsies. A total of at least 9 mucosal pinch biopsies were collected from 3 esophageal regions: 3 proximal, 3 mid, and 3 distal. The peak esophageal intraepithelial eosinophil count at each visit was the maximum of the quantities of eosinophils in the most inflamed hpfs across the 3 regions. If the quantity of eosinophils was missing for 1 or 2 esophageal regions, the peak eosinophil count was the maximum of the quantities of eosinophils from the region(s) where eosinophil quantities were available.

    Time frame: At Week 52

  17. Part B: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eosinophils/High Power Field at Week 52

    Peak esophageal intraepithelial eosinophil count was measured from esophageal biopsies. A total of at least 9 mucosal pinch biopsies were collected from 3 esophageal regions: 3 proximal, 3 mid, and 3 distal. The peak esophageal intraepithelial eosinophil count at each visit was the maximum of the quantities of eosinophils in the most inflamed hpfs across the 3 regions. If the quantity of eosinophils was missing for 1 or 2 esophageal regions, the peak eosinophil count was the maximum of the quantities of eosinophils from the region(s) where eosinophil quantities were available.

    Time frame: At Week 52

  18. Part B: Percent Change From Baseline in Peak Esophageal Intraepithelial Eosinophil Count at Week 52

    Peak esophageal intraepithelial eosinophil count was measured from esophageal biopsies. A total of at least 9 mucosal pinch biopsies were collected from 3 esophageal regions: 3 proximal, 3 mid, and 3 distal. The peak esophageal intraepithelial eosinophil count at each visit was the maximum of the quantities of eosinophils in the most inflamed hpfs across the 3 regions. If the quantity of eosinophils was missing for 1 or 2 esophageal regions, the peak eosinophil count was the maximum of the quantities of eosinophils from the region(s) where eosinophil quantities were available.

    Time frame: Baseline, Week 52

  19. Part B: Change From Baseline in Mean Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) Grade Score at Week 52

    EoE-HSS is a validated histologic scoring system that measures other histological abnormalities in addition to density of eosinophilic infiltration. Severity (grade) and extent (stage) of abnormalities will be scored using a 4-point scale (0 normal; 3 maximum change). Higher total score indicated greater severity \& extent of histological abnormalities. For each of 3 esophageal regions (proximal, mid, and distal), the ratio of the sum of assigned score for each evaluated feature divided by maximum possible score (maximum value is 24) was calculated. The mean grade scores summed over the 3 regions was the final score used in primary analysis, the mean grade score ranged from 0 to 3, with higher score indicating more severe.

    Time frame: Baseline, Week 52

  20. Part B: Change From Baseline in Mean Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) Stage Score at Week 52

    EoE-HSS is a validated histologic scoring system that measures other histological abnormalities in addition to density of eosinophilic infiltration. Severity (grade) and extent (stage) of abnormalities will be scored using a 4-point scale (0 normal; 3 maximum change). Higher total score indicated greater severity \& extent of histological abnormalities. For each of 3 esophageal regions (proximal, mid, and distal), the ratio of the sum of assigned score for each evaluated feature divided by maximum possible score (maximum value is 24) was calculated. The mean stage scores summed over the 3 regions was the final score used in primary analysis, the mean stage score ranged from 0 to 3, with higher score indicating more severe.

    Time frame: Baseline, Week 52

  21. Part B: Absolute Change From Baseline in EoE Endoscopic Reference Total Score (EoE-EREFS) at Week 52

    The EoE-EREFS is a validated endoscopic scoring system for inflammatory and remodeling features of EoE including edema, rings, exudates, furrows, and stricture. The score was assessed in the proximal and distal esophageal regions with each region scored from 0 to 9 with total scores possibly ranging from 0 to 18. Higher scores indicate worse endoscopic inflammatory and remodeling findings.

    Time frame: Baseline, Week 52

  22. Part B: Change From Baseline in the Proportion of Days With 1 or More EoE Signs Measured by Pediatric EoE Sign/Symptom Questionnaire - Caregiver Version (PESQ-C) at Week 52

    PESQ-C is a novel, observer-reported outcome measure intended to be completed independently by caregivers of all pediatric EoE participants in the study.

    Time frame: Baseline, Week 52

  23. Part B: Number of Sign-free Days During the 14-day Period Preceding Week 52 as Measured by the PESQ-C (for Participants Aged ≥1 to <12 Years)

    PESQ-C is a novel, observer-reported outcome measure intended to be completed independently by caregivers of all pediatric EoE participants in the study.

    Time frame: Week 52

  24. Part B: Change From Baseline in the Proportion of Total Segments Within a Day (Night, Morning, Afternoon, Evening) With 1 or More EoE Signs as Measured by the PESQ-C at Week 52

    PESQ-C is a novel, observer-reported outcome measure intended to be completed independently by caregivers of all pediatric EoE participants in the study. The PESQ-C measured the occurrence of signs of EoE and was completed once daily via an electronic diary.

    Time frame: Baseline, Week 52

  25. Part B: Change From Baseline in the Proportion of Days With 1 or More EoE Signs by Pediatric EoE Sign/Symptom Questionnaire - Participant Version (PESQ-P) (for Participants Aged ≥8 to <12 Years) at Week 52

    The PESQ-P was a participant-reported outcome measure intended to be completed independently by participants ≥8 to \<12 years of age. The PESQ-P measured occurrence of signs of EoE and was completed once daily via an electronic diary. Data from a 14-day period preceding the baseline visit and a 14-day period preceding week 16 will be used to calculate the proportion of days with 1 or more EoE symptoms.

    Time frame: Baseline, Week 52

  26. Part B: Number of Symptom-free Days During the 14-day Period Preceding Week 52 as Measured by the PESQ-P (for Participants Aged ≥8 to <12 Years)

    The PESQ-P was a participant-reported outcome measure intended to be completed independently by participants ≥8 to \<12 years of age. The PESQ-P measures the signs of EoE, including stomach pain, heartburn, acid reflux, regurgitation, vomiting, food refusal, and trouble swallowing food.

    Time frame: Week 52

  27. Part B: Change From Baseline in the Proportion of Total Segments Within a Day (Night, Morning, Afternoon, Evening) With 1 or More EoE Signs as Measured by the PESQ-P (for Participants Aged ≥8 to <12 Years) at Week 52

    The PESQ-P was a participant-reported outcome measure intended to be completed independently by EoE participants ≥8 to \<12 years of age. The PESQ-P measured the occurrence of signs of EoE and was completed once daily via an electronic diary. Data from a 14-day period preceding the baseline visit and a 14-day period preceding week 16 will be used to calculate the total time segments within a day (night, morning, afternoon, evening) with 1 or more EoE symptoms.

    Time frame: Baseline, Week 52

  28. Part B: Normalized Enrichment Score (NES) for the Relative Change From Baseline in the EoE Diagnostic Panel (EDP) at Week 52

    A Normalized Enrichment Score (NES) is a way to generate a single numerical value to represent a complex gene expression signature. Changes in NES score represented the overall changes in the expression of that molecular phenotype. The NESs calculated for the EDP reflect the expression at post-baseline relative to Baseline of a gene set that is differentially expressed between esophageal biopsies from EoE participants compared to healthy controls as a way to evaluate normalization of the molecular pathology. For each subject, an NES of 0 indicates no change from baseline, a negative score shows a reduction in disease score (more like normal) and positive score shows worsening (more active disease). NES does not have minimum/maximum score.

    Time frame: Baseline, Week 52

  29. Part B: Normalized Enrichment Score (NES) for the Relative Change From Baseline in the Type 2 Inflammation Signature (T2INF) at Week 52

    A Normalized Enrichment Score (NES) is a way to generate a single numerical value to represent a complex gene expression signature. Changes in NES score represented the overall changes in the expression of that molecular phenotype. The NESs calculated for T2INF reflect the expression at post-baseline relative to Baseline of the pre-specified gene set as a way to evaluate normalization of type 2 inflammation with treatment. For each subject, an NES of 0 indicates no change from baseline, a negative score shows a reduction in disease score (more like normal) and positive score shows worsening (more active disease). NES does not have minimum/maximum score.

    Time frame: Baseline, Week 52

  30. Part B: Change From Baseline in Body Weight for Age Percentile at Week 52

    Body weight for age percentile was calculated based on the growth charts from the Centers for Disease Control and Prevention (CDC) for ages 0 to 20 years (for ages 2 to \<12 years) and World Health Organization (WHO) growth charts for ages 0 to \<2 years (for ages 1 to \<2 years). These charts included a set of smoothed percentiles along with CDC LMS (Lambda-Mu-Sigma) parameters to allow the calculation of percentiles.

    Time frame: Baseline, Week 52

  31. Part B: Change From Baseline in Body Mass Index (BMI) for Age Z-score for Participants ≥2 Years of Age at Week 52

    BMI for age z-score indicates how much higher or lower a participant's BMI for age is relative to a reference growth chart (based on the growth charts from Centers for Disease Control and Prevention \[CDC\] for ages 0 to 20 years \[for ages 2 to \<12 years\]). A z-score of "0" represents the population mean. An increase in the mean change in BMI for age z-score (ie, increase in the standard deviation \[SD\] from the reference growth chart) indicates an increase in BMI for age relative to the reference.

    Time frame: Baseline, Week 52

  32. Part B: Change From Baseline in Weight for Age Z-score at Week 52

    Weight for age z-score indicates how much higher or lower a participant's weight for age is relative to a reference growth chart (based on the growth charts from CDC for ages 0 to 20 years \[for ages 2 to \<12 years\] and World Health Organization (WHO) growth charts for ages 0 to \<2 years \[for ages 1 to \<2 years\]). A z-score of "0" represents the population mean. An increase in the mean change in weight for age z-score (increase in the SD from the reference growth chart) indicates an increase in weight for age relative to the reference.

    Time frame: Baseline, Week 52

  33. Part B: Change From Baseline in Body Weight From Height Z-score at Week 52

    Weight for height z-score indicates how much higher or lower a participant's weight for height is relative to a reference growth chart (based on the growth charts from CDC for ages 0 to 20 years \[for ages 2 to \<12 years\] and WHO growth charts for ages 0 to \<2 years \[for ages 1 to \<2 years\]). A z-score of "0" represents the population mean. An increase in the mean change in weight for height z-score (increase in the SD from the reference growth chart) indicates an increase in weight for height relative to the reference.

    Time frame: Baseline, Week 52

  34. Part B: Concentration of Functional Dupilumab in Serum at Week 32 and 52

    Concentration of functional dupilumab in serum at Week 32 and 52 was reported in this outcome measure.

    Time frame: Week 32 and 52

  35. Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Adverse Events of Special Interest (AESIs) and TEAEs Leading to Permanent Discontinuation of Study Drug

    An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation patient administered with a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. A serious AE was any untoward medical occurrence that at any dose resulted in death, life-threatening, initial or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or a medically important event. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs include both Serious TEAEs and non-serious TEAEs. An AESI was defined as one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate.

    Time frame: From Baseline up to Week 16 in Part A

  36. Part B: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Adverse Events of Special Interest (AESIs) and TEAEs Leading to Permanent Discontinuation of Study Drug

    An AE was defined as any untoward medical occurrence in a participant or clinical investigation patient administered with a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. A serious AE was any untoward medical occurrence that at any dose resulted in death, life-threatening, initial or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or a medically important event. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs include both Serious TEAEs and non-serious TEAEs. An AESI was defined as one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate.

    Time frame: From Week 16 up to Week 52 in Part B

  37. Part A: Number of Participants With Positive Treatment-emergent Antidrug Antibodies (ADA) Response

    Treatment-emergent ADA was defined as a negative result or missing result at baseline with at least one positive post baseline result in the ADA assay. Samples positive in the dupilumab ADA assay were characterized for ADA titers (low, moderate and high). The low treatment-emergent ADA titer as defined as titer level \<1000, moderate as 1000 to 10000 and high as \>10000.

    Time frame: From Baseline up to Week 16 in Part A

  38. Part A: Number of Participants With Positive Treatment-emergent Antidrug Antibodies (ADA) by Maximum Titer Category

    Treatment-emergent ADA was defined as a negative result or missing result at baseline with at least one positive post baseline result in the ADA assay. Samples positive in the dupilumab ADA assay were characterized for ADA titers (low, moderate and high). The low treatment-emergent ADA titer as defined as titer level \<1000, moderate as 1000 to 10000 and high as \>10000.

    Time frame: From Baseline up to Week 16 in Part A

  39. Part B: Number of Participants With Positive Treatment-emergent Antidrug Antibodies (ADA) Response and Titer

    Treatment-emergent ADA was defined as a negative result or missing result at baseline with at least one positive post baseline result in the ADA assay. Samples positive in the dupilumab ADA assay were characterized for ADA titers (low, moderate and high). The low treatment-emergent ADA titer as defined as titer level \<1000, moderate as 1000 to 10000 and high as \>10000. No participant exhibited a treatment-emergent ADA response in Part B and titer was not reported.

    Time frame: From Week 16 up to Week 52 in Part B

  40. Part C: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eos/Hpf At Week 100

    Time frame: At Week 100

  41. Part C: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eos/Hpf At Week 160

    Time frame: At Week 160

  42. Part C: Percent Change in Peak Esophageal Intraepithelial Eosinophil Count (Eos/Hpf) From Baseline to Week 100

    Time frame: Baseline to Week 100

  43. Part C: Percent Change in Peak Esophageal Intraepithelial Eosinophil Count (Eos/Hpf) From Baseline to Week 160

    Time frame: Baseline to Week 160

  44. Part C: Absolute Change in Mean EoE-HSS From Baseline to Week 100

    Time frame: Baseline to Week 100

  45. Part C: Absolute Change in Mean EoE-HSS From Baseline to Week 160

    Time frame: Baseline to Week 160

  46. Part C: Absolute Change in EoE-EREFS From Baseline to Week 100

    Time frame: Baseline to Week 100

  47. Part C: Absolute Change in EoE-EREFS From Baseline to Week 160

    Time frame: Baseline to Week 160

  48. Part C: Change in Total Score as Measured by the PEESSv2.0- Caregiver Version Questionnaire From Baseline to Week 100

    The PEESSv2.0-C is a caregiver-reported outcome measure that assesses the frequency and severity of EoE symptoms among pediatric participants. The PEESSv2.0-C consists of 20 items and has a one-month recall period. Each item had a 0-4 scale, which was transformed to 0-100 as follows: 0 = 0, 1 = 25, 2 = 50, 3 = 75, 4 = 100. The mean total PEESSv2.0 score was computed as the sum of all the item scores over the number of items answered. The total PEESSv2.0-C score ranges from 0 to 100 where higher scores indicate greater symptom burden among pediatric EoE participants.

    Time frame: Baseline to Week 100

  49. Part C: NES for the Relative Change in the EDP Transcriptome Signature From Baseline to Week 100

    A Normalized Enrichment Score (NES) is a way to generate a single numerical value to represent a complex gene expression signature. Changes in NES score represented the overall changes in the expression of that molecular phenotype. The NESs calculated for the EDP reflect the expression at post-baseline relative to Baseline of a gene set that is differentially expressed between esophageal biopsies from EoE participants compared to healthy controls as a way to evaluate normalization of the molecular pathology. For each subject, an NES of 0 indicates no change from baseline, a negative score shows a reduction in disease score (more like normal) and positive score shows worsening (more active disease). NES does not have minimum/maximum score.

    Time frame: Baseline to Week 100

  50. Part C: NES for the Relative Change in the EDP Transcriptome Signature From Baseline to Week 160

    A Normalized Enrichment Score (NES) is a way to generate a single numerical value to represent a complex gene expression signature. Changes in NES score represented the overall changes in the expression of that molecular phenotype. The NESs calculated for the EDP reflect the expression at post-baseline relative to Baseline of a gene set that is differentially expressed between esophageal biopsies from EoE participants compared to healthy controls as a way to evaluate normalization of the molecular pathology. For each subject, an NES of 0 indicates no change from baseline, a negative score shows a reduction in disease score (more like normal) and positive score shows worsening (more active disease). NES does not have minimum/maximum score.

    Time frame: Baseline to Week 160

  51. Part C: NES for the Relative Change in the Type 2 Inflammation Transcriptome Signature Baseline to Week 100

    Time frame: Baseline to Week 100

  52. Part C: NES for the Relative Change in the Type 2 Inflammation Transcriptome Signature From Baseline to Week 160

    Time frame: Baseline to Week 160

  53. Part C: Change in Body Weight for Age Percentile From Baseline up to Week 100

    Body weight for age percentile was calculated based on the growth charts from the Centers for Disease Control and Prevention (CDC) for ages 0 to 20 years (for ages 2 to \<12 years) and World Health Organization (WHO) growth charts for ages 0 to \<2 years (for ages 1 to \<2 years). These charts included a set of smoothed percentiles along with CDC LMS (Lambda-Mu-Sigma) parameters to allow the calculation of percentiles.

    Time frame: Baseline up to Week 100

  54. Part C: Change in Body Mass Index for Age Z-score From Baseline up to Week 100

    Difference in the 100-week change from baseline in BMI-for-age Z-score. BMI-for-age Z-scores are based on a reference growth chart (based on the growth charts from Centers for Disease Control and Prevention \[CDC\] for ages 0 to 20 years \[for ages 2 to \<12 years\]. A z-score of "0" represents the population mean. The Z-score indicates the number of standard deviations away from the mean of the reference population. A negative Z-score indicates values lower than the population mean while a positive Z-score indicates values higher than the population mean.

    Time frame: Baseline up to Week 100

  55. Part C: Change in Weight for Age Z-score From Baseline up to Week 100

    Difference in the 100-week change from baseline in weight-for-age Z-score. Weight-for-age Z-scores are based on a reference growth chart (based on the growth charts from Centers for Disease Control and Prevention \[CDC\] for ages 0 to 20 years \[for ages 2 to \<12 years\]. A z-score of "0" represents the population mean. The Z-score indicates the number of standard deviations away from the mean of the reference population. A negative Z-score indicates values lower than the population mean while a positive Z-score indicates values higher than the population mean.

    Time frame: Baseline up to Week 100

  56. Part C: Change in Weight for Age Z-score From Baseline up to Week 160

    Weight for age z-score indicates how much higher or lower a participant's weight for age is relative to a reference growth chart (based on the growth charts from CDC for ages 0 to 20 years \[for ages 2 to \<12 years\] and World Health Organization (WHO) growth charts for ages 0 to \<2 years \[for ages 1 to \<2 years\]). An increase in the mean change in weight for age z-score (increase in the SD from the reference growth chart) indicates an increase in weight for age relative to the reference.

    Time frame: Baseline up to Week 160

  57. Part C: Change in Weight for Height Z-score From Baseline up to Week 100

    Difference in the 100-week change from baseline in Weight for height Z-score. Weight for height Z-scores are based on a reference growth chart (based on the growth charts from Centers for Disease Control and Prevention \[CDC\] for ages 0 to 20 years \[for ages 2 to \<12 years\]. A z-score of "0" represents the population mean. The Z-score indicates the number of standard deviations away from the mean of the reference population. A negative Z-score indicates values lower than the population mean while a positive Z-score indicates values higher than the population mean.

    Time frame: Baseline up to Week 100

  58. Part C: Change in Weight for Height Z-score From Baseline up to Week 160

    Weight for height z-score indicates how much higher or lower a participant's weight for height is relative to a reference growth chart (based on the growth charts from CDC for ages 0 to 20 years \[for ages 2 to \<12 years\] and WHO growth charts for ages 0 to \<2 years \[for ages 1 to \<2 years\]). An increase in the mean change in weight for height z-score (increase in the SD from the reference growth chart) indicates an increase in weight for height relative to the reference.

    Time frame: Baseline up to Week 160

  59. Part C: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eos/Hpf (400×) at Week 100

    Time frame: At Week 100

  60. Part C: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eos/Hpf (400×) at Week 160

    Time frame: At Week 160

  61. Part C: Percentage of Participants (With Food Elimination Diet Regimens at Baseline) That Have a Re-introduction of a Previously Eliminated Food Group From Baseline up to Week 100

    Time frame: Baseline up to Week 100

  62. Part C: Percentage of Participants (With Food Elimination Diet Regimens at Baseline) That Have a Re-introduction of a Previously Eliminated Food Group From Baseline up to Week 160

    Time frame: Baseline up to Week 160

  63. Part C: Number of Participants With TEAEs

    Time frame: Up to Week 152

  64. Part C: Number of Participants With Treatment-emergent SAEs

    Time frame: Up to Week 152

  65. Part C: Number of Participants With Treatment-emergent AESIs

    Time frame: Up to Week 152

  66. Part C: Number of Participants With TEAEs Leading to Permanent Discontinuation of Study Treatment

    Time frame: Up to Week 152

  67. Part C: Number of Participants With Treatment-emergent ADA Responses

    Time frame: From Week 52 up to Week 152

  68. Part C: Concentration of Functional Dupilumab in Serum at Week 100

    Time frame: At Week 100

07

Results

Posted Aug 27, 2024

Participant flow

Part A (16 Weeks)
Participant flow — Part A (16 Weeks)
MilestonePart A: Pooled Placebo (Placebo)Part A: Dupilumab Low DosePart A: Dupilumab High DosePart B: Placebo to Dupilumab Low DosePart B: Placebo to Dupilumab High DosePart B: Dupilumab Low Dose to Dupilumab Low DosePart B: Dupilumab High Dose to Dupilumab High DosePart C: Dupilumab
Started34313700000
Completed33293700000
Not completed12000000
Withdrew: Adverse event10000000
Withdrew: Physician decision01000000
Withdrew: Withdrawal by subject01000000
Part B (36 Weeks)
Participant flow — Part B (36 Weeks)
MilestonePart A: Pooled Placebo (Placebo)Part A: Dupilumab Low DosePart A: Dupilumab High DosePart B: Placebo to Dupilumab Low DosePart B: Placebo to Dupilumab High DosePart B: Dupilumab Low Dose to Dupilumab Low DosePart B: Dupilumab High Dose to Dupilumab High DosePart C: Dupilumab
Started000141829370
Completed000141829360
Not completed00000010
Withdrew: Adverse event00000010
Part C: (Up to Wk108+12Wk Follow-up)
Participant flow — Part C: (Up to Wk108+12Wk Follow-up)
MilestonePart A: Pooled Placebo (Placebo)Part A: Dupilumab Low DosePart A: Dupilumab High DosePart B: Placebo to Dupilumab Low DosePart B: Placebo to Dupilumab High DosePart B: Dupilumab Low Dose to Dupilumab Low DosePart B: Dupilumab High Dose to Dupilumab High DosePart C: Dupilumab
Started000000061
Completed00000008
Not completed000000053
Withdrew: Physician decision00000003
Withdrew: Withdrawal by subject000000016
Withdrew: Protocol violation00000002
Withdrew: Other000000032

Outcome measures

PrimaryPart A: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of Less Than or Equal to (≤) 6 Eosinophils/High Power Field (Eos/Hpf) at Week 16

Peak esophageal intraepithelial eosinophil count was measured from esophageal biopsies. A total of at least 9 mucosal pinch biopsies were collected from 3 esophageal regions: 3 proximal, 3 mid, and 3 distal. The peak esophageal intraepithelial eosinophil count at each visit was the maximum of the quantities of eosinophils in the most inflamed hpfs across the 3 regions. If the quantity of eosinophils was missing for 1 or 2 esophageal regions, the peak eosinophil count was the maximum of the quantities of eosinophils from the region(s) where eosinophil quantities were available.

Time frame:
At Week 16
Reported as:
Number · percentage of participants
Part A: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of Less Than or Equal to (≤) 6 Eosinophils/High Power Field (Eos/Hpf) at Week 16
percentage of participantsPart A: Pooled PlaceboPart A: Dupilumab High DosePart A: Dupilumab Low Dose
Part A: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of Less Than or Equal to (≤) 6 Eosinophils/High Power Field (Eos/Hpf) at Week 162.9 (0.07 to 15.33)67.6 (50.21 to 81.99)58.1 (39.08 to 75.45)
Statistical analysis
  • Part A: Pooled Placebo vs Part A: Dupilumab High Dose · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 53.8 · 95% CI 7.37 to 392.82Odds ratio and corresponding Confidence Interval (CI) are based on CMH test stratified by baseline weight group.
  • Part A: Pooled Placebo vs Part A: Dupilumab Low Dose · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 46.7 · 95% CI 5.47 to 399.54Odds ratio and corresponding CI are based on CMH test stratified by baseline weight group.
SecondaryPart A: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eosinophils/High Power Field at Week 16

Peak esophageal intraepithelial eosinophil count was measured from esophageal biopsies. A total of at least 9 mucosal pinch biopsies were collected from 3 esophageal regions: 3 proximal, 3 mid, and 3 distal. The peak esophageal intraepithelial eosinophil count at each visit was the maximum of the quantities of eosinophils in the most inflamed hpfs across the 3 regions. If the quantity of eosinophils was missing for 1 or 2 esophageal regions, the peak eosinophil count was the maximum of the quantities of eosinophils from the region(s) where eosinophil quantities were available.

Time frame:
At Week 16
Reported as:
Number · percentage of participants
Part A: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eosinophils/High Power Field at Week 16
percentage of participantsPart A: Pooled PlaceboPart A: Dupilumab High DosePart A: Dupilumab Low Dose
Part A: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eosinophils/High Power Field at Week 162.9 (0.07 to 15.33)83.8 (67.99 to 93.81)67.7 (48.63 to 83.32)
Statistical analysis
  • Part A: Pooled Placebo vs Part A: Dupilumab High Dose · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 178.0 · 95% CI 18.84 to 1682.4Odds ratio and corresponding CI are based on CMH test stratified by baseline weight group
  • Part A: Pooled Placebo vs Part A: Dupilumab Low Dose · Cochran-Mantel-Haenszel · p = <0.0001 (P-value is not adjusted for multiple comparisons) · Odds ratio (or): 55.3 · 95% CI 7.45 to 410.23Odds ratio and corresponding CI are based on CMH test stratified by baseline weight group
SecondaryPart A: Percent Change From Baseline in Peak Esophageal Intraepithelial Eosinophil Count at Week 16

Peak esophageal intraepithelial eosinophil count was measured from esophageal biopsies. A total of at least 9 mucosal pinch biopsies were collected from 3 esophageal regions: 3 proximal, 3 mid, and 3 distal. The peak esophageal intraepithelial eosinophil count at each visit was the maximum of the quantities of eosinophils in the most inflamed hpfs across the 3 regions. If the quantity of eosinophils was missing for 1 or 2 esophageal regions, the peak eosinophil count was the maximum of the quantities of eosinophils from the region(s) where eosinophil quantities were available. Least squared (LS) mean and standard error (SE) from analysis of covariance (ANCOVA) model with Baseline measurement as covariate and the treatment, baseline weight group strata as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · percent change
Part A: Percent Change From Baseline in Peak Esophageal Intraepithelial Eosinophil Count at Week 16
percent changePart A: Pooled PlaceboPart A: Dupilumab High DosePart A: Dupilumab Low Dose
Part A: Percent Change From Baseline in Peak Esophageal Intraepithelial Eosinophil Count at Week 1620.98 ± 12.23-86.09 ± 11.84-77.93 ± 12.89
Statistical analysis
  • Part A: Pooled Placebo vs Part A: Dupilumab High Dose · ANCOVA · p = <0.0001 · Ls mean difference: -107.07 · 95% CI -139.249 to -74.900CI was based on treatment difference (Dupilumab group vs. placebo) of the LS mean change using ANCOVA model with baseline measurement as covariate and the treatment, baseline weight group strata as fixed factors.
  • Part A: Pooled Placebo vs Part A: Dupilumab Low Dose · ANCOVA · p = <0.0001 (P-value is not adjusted for multiple comparisons) · Ls mean difference: -98.92 · 95% CI -132.463 to -65.370CI was based on treatment difference (Dupilumab group vs. placebo) of the LS mean change using ANCOVA model with baseline measurement as covariate and the treatment, baseline weight group strata as fixed factors.
SecondaryPart A: Change From Baseline in Mean Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) Grade Score at Week 16

EoE-HSS is a validated histologic scoring system that measures other histological abnormalities in addition to density of eosinophilic infiltration. Severity (grade) and extent (stage) of abnormalities will be scored using a 4-point scale (0 normal; 3 maximum change). Higher total score indicated greater severity \& extent of histological abnormalities. For each of 3 esophageal regions (proximal, mid, and distal), the ratio of the sum of assigned score for each evaluated feature divided by maximum possible score (maximum value is 24) was calculated. The mean grade scores summed over the 3 regions was the final score used in primary analysis, the mean grade score ranged from 0 to 3, with higher score indicating more severe.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Score on a scale
Part A: Change From Baseline in Mean Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) Grade Score at Week 16
Score on a scalePart A: Pooled PlaceboPart A: Dupilumab High DosePart A: Dupilumab Low Dose
Part A: Change From Baseline in Mean Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) Grade Score at Week 160.023 ± 0.0498-0.879 ± 0.0481-0.757 ± 0.0524
Statistical analysis
  • Part A: Pooled Placebo vs Part A: Dupilumab High Dose · ANCOVA · p = <0.0001 · Ls mean difference: -0.902 · 95% CI -1.0325 to -0.7714CI was based on treatment difference (Dupilumab group vs. placebo) of the LS mean change using ANCOVA model with baseline measurement as covariate and the treatment, baseline weight group strata as fixed factors.
  • Part A: Pooled Placebo vs Part A: Dupilumab Low Dose · ANCOVA · p = <0.0001 (P-value is not adjusted for multiple comparisons) · Ls mean difference: -0.780 · 95% CI -0.9170 to -0.6440CI was based on treatment difference (Dupilumab group vs. placebo) of the LS mean change using ANCOVA model with baseline measurement as covariate and the treatment, baseline weight group strata as fixed factors.
SecondaryPart A: Change From Baseline in Mean Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) Stage Score at Week 16

EoE-HSS is a validated histologic scoring system that measures other histological abnormalities in addition to density of eosinophilic infiltration. Severity (grade) and extent (stage) of abnormalities will be scored using a 4-point scale (0 normal; 3 maximum change). Higher total score indicated greater severity \& extent of histological abnormalities. For each of 3 esophageal regions (proximal, mid, and distal), the ratio of the sum of assigned score for each evaluated feature divided by maximum possible score (maximum value is 24) was calculated. The mean stage scores summed over the 3 regions was the final score used in primary analysis, the mean stage score ranged from 0 to 3, with higher score indicating more severe.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Score on a scale
Part A: Change From Baseline in Mean Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) Stage Score at Week 16
Score on a scalePart A: Pooled PlaceboPart A: Dupilumab High DosePart A: Dupilumab Low Dose
Part A: Change From Baseline in Mean Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) Stage Score at Week 160.048 ± 0.0482-0.835 ± 0.0466-0.721 ± 0.0507
Statistical analysis
  • Part A: Pooled Placebo vs Part A: Dupilumab High Dose · ANCOVA · p = <0.0001 · Ls mean difference: -0.883 · 95% CI -1.0095 to -0.7568CI was based on treatment difference (Dupilumab group vs. placebo) of the LS mean change using ANCOVA model with baseline measurement as covariate and the treatment, baseline weight group strata as fixed factors.
  • Part A: Pooled Placebo vs Part A: Dupilumab Low Dose · ANCOVA · p = <0.0001 (P-value is not adjusted for multiple comparisons) · Ls mean difference: -0.769 · 95% CI -0.9013 to -0.6362CI was based on treatment difference (Dupilumab group vs. placebo) of the LS mean change using ANCOVA model with baseline measurement as covariate and the treatment, baseline weight group strata as fixed factors.
SecondaryPart A: Normalized Enrichment Score (NES) for the Relative Change From Baseline in the Type 2 Inflammation Signature (T2INF) at Week 16

A Normalized Enrichment Score (NES) is a way to generate a single numerical value to represent a complex gene expression signature. Changes in NES score represented the overall changes in the expression of that molecular phenotype. The NESs calculated for T2INF reflect the expression at Week 16 relative to Baseline of the pre-specified gene set as a way to evaluate normalization of type 2 inflammation with treatment. For each subject, an NES of 0 indicates no change from baseline, a negative score shows a reduction in disease score (more like normal) and positive score shows worsening (more active disease). NES does not have a minimum/maximum score.

Time frame:
Baseline, Week 16
Reported as:
Median · Score on a scale
Part A: Normalized Enrichment Score (NES) for the Relative Change From Baseline in the Type 2 Inflammation Signature (T2INF) at Week 16
Score on a scalePart A: Pooled PlaceboPart A: Dupilumab High DosePart A: Dupilumab Low Dose
Part A: Normalized Enrichment Score (NES) for the Relative Change From Baseline in the Type 2 Inflammation Signature (T2INF) at Week 160.34 (-1.84 to 1.65)-1.895 (-2.03 to -1.61)-1.930 (-2.00 to -1.39)
Statistical analysis
  • Part A: Pooled Placebo vs Part A: Dupilumab High Dose · Wilcoxon rank-sum test · p = <0.0001 · Hodges-lehmann estimator: -2.220 · 95% CI -2.4400 to -1.9500Median Difference is Dupilumab minus Placebo
  • Part A: Pooled Placebo vs Part A: Dupilumab Low Dose · Wilcoxon rank-sum test · p = <0.0001 (P-value is not adjusted for multiple comparisons) · Hodges-lehmann estimator: -2.190 · 95% CI -2.4500 to -1.8200Median Difference is Dupilumab minus Placebo
SecondaryPart A: Normalized Enrichment Score (NES) for the Relative Change From Baseline in the Eosinophilic Esophagitis (EoE) Diagnostic Panel (EDP) at Week 16

A Normalized Enrichment Score (NES) is a way to generate a single numerical value to represent a complex gene expression signature. Changes in NES score represented the overall changes in the expression of that molecular phenotype. The NESs calculated for the EDP reflect the expression at Week 16 relative to Baseline of a gene set that is differentially expressed between esophageal biopsies from EoE participants compared to healthy controls as a way to evaluate normalization of the molecular pathology. For each subject, an NES of 0 indicates no change from baseline, a negative score shows a reduction in disease score (more like normal) and positive score shows worsening (more active disease). NES does not have minimum/maximum score.

Time frame:
Baseline, Week 16
Reported as:
Median · Score on a scale
Part A: Normalized Enrichment Score (NES) for the Relative Change From Baseline in the Eosinophilic Esophagitis (EoE) Diagnostic Panel (EDP) at Week 16
Score on a scalePart A: Pooled PlaceboPart A: Dupilumab High DosePart A: Dupilumab Low Dose
Part A: Normalized Enrichment Score (NES) for the Relative Change From Baseline in the Eosinophilic Esophagitis (EoE) Diagnostic Panel (EDP) at Week 160.180 (-2.53 to 2.39)-2.630 (-2.85 to -2.25)-2.710 (-2.84 to -0.80)
Statistical analysis
  • Part A: Pooled Placebo vs Part A: Dupilumab High Dose · Wilcoxon rank-sum test · p = <0.0001 · Hodges-lehmann estimator: -2.840 · 95% CI -3.3500 to -1.9600Median Difference is Dupilumab minus Placebo
  • Part A: Pooled Placebo vs Part A: Dupilumab Low Dose · Wilcoxon rank-sum test · p = <0.0001 (P-value is not adjusted for multiple comparisons) · Hodges-lehmann estimator: -2.700 · 95% CI -3.3100 to -1.6200Median Difference is Dupilumab minus Placebo
SecondaryPart A: Absolute Change From Baseline in EoE Endoscopic Reference Total Score (EoE-EREFS) at Week 16

The EoE-EREFS is a validated endoscopic scoring system for inflammatory and remodeling features of EoE including edema, rings, exudates, furrows, and stricture. The score was assessed in the proximal and distal esophageal regions with each region scored from 0 to 9 with total scores ranging from 0 to 18. Higher scores indicate worse endoscopic inflammatory and remodeling findings.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Part A: Absolute Change From Baseline in EoE Endoscopic Reference Total Score (EoE-EREFS) at Week 16
score on a scalePart A: Pooled PlaceboPart A: Dupilumab High DosePart A: Dupilumab Low Dose
Part A: Absolute Change From Baseline in EoE Endoscopic Reference Total Score (EoE-EREFS) at Week 160.3 ± 0.45-3.5 ± 0.42-3.0 ± 0.48
Statistical analysis
  • Part A: Pooled Placebo vs Part A: Dupilumab High Dose · ANCOVA · p = <0.0001 · Ls mean difference: -3.8 · 95% CI -4.94 to -2.63CI was based on treatment difference (Dupilumab group vs. placebo) of the LS mean change using ANCOVA model with baseline measurement as covariate and the treatment, baseline weight group strata as fixed factors.
  • Part A: Pooled Placebo vs Part A: Dupilumab Low Dose · ANCOVA · p = <0.0001 (P-value is not adjusted for multiple comparisons) · Ls mean difference: -3.3 · 95% CI -4.59 to -2.10CI was based on treatment difference (Dupilumab group vs. placebo) of the LS mean change using ANCOVA model with baseline measurement as covariate and the treatment, baseline weight group strata as fixed factors.
SecondaryPart A: Change From Baseline in the Proportion of Days With 1 or More EoE Signs as Measured by Pediatric EoE Sign/Symptom Questionnaire - Caregiver Version (PESQ-C) at Week 16 (for Participants Aged ≥1 to <12 Years)

PESQ-C is a novel, observer-reported outcome measure intended to be completed independently by caregivers of all pediatric EoE participants in the study. PESQ-C measures the signs of EoE observed by the caregiver, including stomach pain, heartburn, acid reflux, regurgitation, vomiting, food refusal, and trouble swallowing food. Data from a 14-day period preceding the baseline visit and a 14-day period preceding week 16 will be used to calculate the proportion of days with 1 or more EoE symptoms.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · proportion of days
Part A: Change From Baseline in the Proportion of Days With 1 or More EoE Signs as Measured by Pediatric EoE Sign/Symptom Questionnaire - Caregiver Version (PESQ-C) at Week 16 (for Participants Aged ≥1 to <12 Years)
proportion of daysPart A: Pooled PlaceboPart A: Dupilumab High DosePart A: Dupilumab Low Dose
Part A: Change From Baseline in the Proportion of Days With 1 or More EoE Signs as Measured by Pediatric EoE Sign/Symptom Questionnaire - Caregiver Version (PESQ-C) at Week 16 (for Participants Aged ≥1 to <12 Years)-0.17 ± 0.054-0.28 ± 0.052-0.18 ± 0.060
Statistical analysis
  • Part A: Pooled Placebo vs Part A: Dupilumab High Dose · ANCOVA · p = 0.1526 · Ls mean difference: -0.10 · 95% CI -0.244 to 0.038CI was based on treatment difference (Dupilumab group vs. placebo) of the LS mean change using ANCOVA model with baseline measurement as covariate and the treatment, baseline weight group strata as fixed factors.
  • Part A: Pooled Placebo vs Part A: Dupilumab Low Dose · ANCOVA · p = 0.9533 (P-value is not adjusted for multiple comparisons) · Ls mean difference: -0.00 · 95% CI -0.155 to 0.146CI was based on treatment difference (Dupilumab group vs. placebo) of the LS mean change using ANCOVA model with baseline measurement as covariate and the treatment, baseline weight group strata as fixed factors.
SecondaryPart A: Number of Sign-free Days During the 14-day Period Preceding Week 16 as Measured by the PESQ-C (for Participants Aged ≥1 to <12 Years)

PESQ-C is a novel, observer-reported outcome measure intended to be completed independently by caregivers of all pediatric EoE participants in the study. The PESQ-C measures the signs of EoE observed by the caregiver, including stomach pain, heartburn, acid reflux, regurgitation, vomiting, food refusal, and trouble swallowing food. WOCF approach was used for imputing the missing data due to rescue treatment/AE/lack of efficacy, and the multiple imputations approach was used for the missing data due to other reasons. LS mean SE derived from ANCOVA model.

Time frame:
Week 16
Reported as:
Least squares mean · sign-free days
Part A: Number of Sign-free Days During the 14-day Period Preceding Week 16 as Measured by the PESQ-C (for Participants Aged ≥1 to <12 Years)
sign-free daysPart A: Pooled PlaceboPart A: Dupilumab High DosePart A: Dupilumab Low Dose
Part A: Number of Sign-free Days During the 14-day Period Preceding Week 16 as Measured by the PESQ-C (for Participants Aged ≥1 to <12 Years)8.93 ± 0.75610.38 ± 0.7358.93 ± 0.840
Statistical analysis
  • Part A: Pooled Placebo vs Part A: Dupilumab High Dose · ANCOVA · p = 0.1507 (P-value is not adjusted for multiple comparisons) · Ls mean difference: 1.45 · 95% CI -0.527 to 3.422CI was based on treatment difference (Dupilumab group vs. placebo) of the LS mean change using ANCOVA model with baseline measurement as covariate and the treatment, baseline weight group strata as fixed factors.
  • Part A: Pooled Placebo vs Part A: Dupilumab Low Dose · ANCOVA · p = 0.9965 (P-value is not adjusted for multiple comparisons) · Ls mean difference: 0.00 · 95% CI -2.107 to 2.117CI was based on treatment difference (Dupilumab group vs. placebo) of the LS mean change using ANCOVA model with baseline measurement as covariate and the treatment, baseline weight group strata as fixed factors.
SecondaryPart A: Change From Baseline in the Proportion of Total Segments Within a Day (Night, Morning, Afternoon, Evening) With 1 or More EoE Signs as Measured by the PESQ-C at Week 16

PESQ-C is a novel, observer-reported outcome measure intended to be completed independently by caregivers of all pediatric EoE participants in the study. The PESQ-C measured the occurrence of signs of EoE and was completed once daily via an electronic diary. Data from a 14-day period preceding the baseline visit and a 14-day period preceding week 16 will be used to calculate the total time segments within a day (night, morning, afternoon, evening) with 1 or more EoE symptoms.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · proportion of segments
Part A: Change From Baseline in the Proportion of Total Segments Within a Day (Night, Morning, Afternoon, Evening) With 1 or More EoE Signs as Measured by the PESQ-C at Week 16
proportion of segmentsPart A: Pooled PlaceboPart A: Dupilumab High DosePart A: Dupilumab Low Dose
Part A: Change From Baseline in the Proportion of Total Segments Within a Day (Night, Morning, Afternoon, Evening) With 1 or More EoE Signs as Measured by the PESQ-C at Week 16-0.11 ± 0.032-0.16 ± 0.031-0.09 ± 0.036
Statistical analysis
  • Part A: Pooled Placebo vs Part A: Dupilumab High Dose · ANCOVA · p = 0.2064 (P-value is not adjusted for multiple comparisons) · Ls mean difference: -0.05 · 95% CI -0.139 to 0.030CI was based on treatment difference (Dupilumab group vs. placebo) of the LS mean change using ANCOVA model with baseline measurement as covariate and the treatment, baseline weight group strata as fixed factors.
  • Part A: Pooled Placebo vs Part A: Dupilumab Low Dose · ANCOVA · p = 0.6361 (P-value is not adjusted for multiple comparisons) · Ls mean difference: 0.02 · 95% CI -0.069 to 0.112CI was based on treatment difference (Dupilumab group vs. placebo) of the LS mean change using ANCOVA model with baseline measurement as covariate and the treatment, baseline weight group strata as fixed factors.
SecondaryPart A: Change From Baseline in the Proportion of Days With 1 or More EoE Signs by Pediatric EoE Sign/Symptom Questionnaire - Participant Version (PESQ-P) (for Participants Aged ≥8 to <12 Years) at Week 16

The PESQ-P was a participant-reported outcome measure intended to be completed independently by participants ≥8 to \<12 years of age. The PESQ-P measured occurrence of signs of EoE and was completed once daily via an electronic diary. Data from a 14-day period preceding the baseline visit and a 14-day period preceding week 16 will be used to calculate the proportion of days with 1 or more EoE symptoms.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · proportion of days
Part A: Change From Baseline in the Proportion of Days With 1 or More EoE Signs by Pediatric EoE Sign/Symptom Questionnaire - Participant Version (PESQ-P) (for Participants Aged ≥8 to <12 Years) at Week 16
proportion of daysPart A: Pooled PlaceboPart A: Dupilumab High DosePart A: Dupilumab Low Dose
Part A: Change From Baseline in the Proportion of Days With 1 or More EoE Signs by Pediatric EoE Sign/Symptom Questionnaire - Participant Version (PESQ-P) (for Participants Aged ≥8 to <12 Years) at Week 16-0.26 ± 0.068-0.13 ± 0.077-0.16 ± 0.067
Statistical analysis
  • Part A: Pooled Placebo vs Part A: Dupilumab High Dose · ANCOVA · p = 0.2086 (P-value is not adjusted for multiple comparisons) · Ls mean difference: 0.13 · 95% CI -0.072 to 0.330CI was based on treatment difference (Dupilumab group vs. placebo) of the LS mean change using ANCOVA model with baseline measurement as covariate and the treatment, baseline weight group strata as fixed factors.
  • Part A: Pooled Placebo vs Part A: Dupilumab Low Dose · ANCOVA · p = 0.2975 (P-value is not adjusted for multiple comparisons) · Ls mean difference: 0.10 · 95% CI -0.088 to 0.286CI was based on treatment difference (Dupilumab group vs. placebo) of the LS mean change using ANCOVA model with baseline measurement as covariate and the treatment, baseline weight group strata as fixed factors.
SecondaryPart A: Number of Symptom-free Days During the 14-day Period Preceding Week 16 as Measured by the PESQ-P (for Participants Aged ≥8 to <12 Years)

The PESQ-P was a participant-reported outcome measure intended to be completed independently by EoE participants ≥8 to \<12 years of age. The PESQ-P measures the signs of EoE, including stomach pain, heartburn, acid reflux, regurgitation, vomiting, food refusal, and trouble swallowing food. The PESQ-P score was calculated based on the daily responses over a 14-day period (i.e., the 14 days prior to the baseline visit and the week 16 visit). The score ranges from 0 to 1. WOCF approach was used for imputing the missing data due to rescue treatment/AE/lack of efficacy, and the multiple imputations approach was used for the missing data due to other reasons. LS Mean SE from ANCOVA.

Time frame:
Week 16
Reported as:
Least squares mean · sign-free days
Part A: Number of Symptom-free Days During the 14-day Period Preceding Week 16 as Measured by the PESQ-P (for Participants Aged ≥8 to <12 Years)
sign-free daysPart A: Pooled PlaceboPart A: Dupilumab High DosePart A: Dupilumab Low Dose
Part A: Number of Symptom-free Days During the 14-day Period Preceding Week 16 as Measured by the PESQ-P (for Participants Aged ≥8 to <12 Years)10.49 ± 0.9538.69 ± 1.0819.13 ± 0.936
Statistical analysis
  • Part A: Pooled Placebo vs Part A: Dupilumab High Dose · ANCOVA · p = 0.2085 (P-value is not adjusted for multiple comparisons) · Ls mean difference: -1.80 · 95% CI -4.615 to 1.007CI was based on treatment difference (Dupilumab group vs. placebo) of the LS mean change using ANCOVA model with baseline measurement as covariate and the treatment, baseline weight group strata as fixed factors.
  • Part A: Pooled Placebo vs Part A: Dupilumab Low Dose · ANCOVA · p = 0.3098 (P-value is not adjusted for multiple comparisons) · Ls mean difference: -1.36 · 95% CI -3.972 to 1.260CI was based on treatment difference (Dupilumab group vs. placebo) of the LS mean change using ANCOVA model with baseline measurement as covariate and the treatment, baseline weight group strata as fixed factors.
SecondaryPart A: Change From Baseline in the Proportion of Total Segments Within a Day (Night, Morning, Afternoon, Evening) With 1 or More EoE Signs as Measured by the PESQ-P (for Participants Aged ≥8 to <12 Years) at Week 16

The PESQ-P was a participant-reported outcome measure intended to be completed independently by EoE participants ≥8 to \<12 years of age. The PESQ-P measured the occurrence of signs of EoE and was completed once daily via an electronic diary. Data from a 14-day period preceding the baseline visit and a 14-day period preceding week 16 will be used to calculate the total time segments within a day (night, morning, afternoon, evening) with 1 or more EoE symptoms.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · proportion of segments
Part A: Change From Baseline in the Proportion of Total Segments Within a Day (Night, Morning, Afternoon, Evening) With 1 or More EoE Signs as Measured by the PESQ-P (for Participants Aged ≥8 to <12 Years) at Week 16
proportion of segmentsPart A: Pooled PlaceboPart A: Dupilumab High DosePart A: Dupilumab Low Dose
Part A: Change From Baseline in the Proportion of Total Segments Within a Day (Night, Morning, Afternoon, Evening) With 1 or More EoE Signs as Measured by the PESQ-P (for Participants Aged ≥8 to <12 Years) at Week 16-0.15 ± 0.040-0.08 ± 0.045-0.08 ± 0.039
Statistical analysis
  • Part A: Pooled Placebo vs Part A: Dupilumab High Dose · ANCOVA · p = 0.2360 (P-value is not adjusted for multiple comparisons) · Ls mean difference: 0.07 · 95% CI -0.046 to 0.186CI was based on treatment difference (Dupilumab group vs. placebo) of the LS mean change using ANCOVA model with baseline measurement as covariate and the treatment, baseline weight group strata as fixed factors.
  • Part A: Pooled Placebo vs Part A: Dupilumab Low Dose · ANCOVA · p = 0.1939 (P-value is not adjusted for multiple comparisons) · Ls mean difference: 0.07 · 95% CI -0.037 to 0.181CI was based on treatment difference (Dupilumab group vs. placebo) of the LS mean change using ANCOVA model with baseline measurement as covariate and the treatment, baseline weight group strata as fixed factors.
SecondaryPart A: Change From Baseline in Total Score as Measured by the Pediatric Eosinophilic Esophagitis Symptom Score (PEESS) Version 2.0 Caregiver Version (PEESSv2.0-C) at Week 16

The PEESSv2.0-C is a caregiver-reported outcome measure that assesses the frequency and severity of EoE symptoms among pediatric participants. The PEESSv2.0-C consists of 20 items and has a one-month recall period. Each item had a 0-4 scale, which was transformed to 0-100 as follows: 0 = 0, 1 = 25, 2 = 50, 3 = 75, 4 = 100. The mean total PEESSv2.0 score was computed as the sum of all the item scores over the number of items answered. The total PEESSv2.0-C score ranges from 0 to 100 where higher scores indicate greater symptom burden among pediatric EoE participants. Values after first rescue treatment use were set to missing (censoring). WOCF approach was used for imputing the missing data due to rescue treatment/AE/lack of efficacy, and the MI approach was used for the missing data due to other reasons. LS mean SE from ANCOVA model.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Part A: Change From Baseline in Total Score as Measured by the Pediatric Eosinophilic Esophagitis Symptom Score (PEESS) Version 2.0 Caregiver Version (PEESSv2.0-C) at Week 16
score on a scalePart A: Pooled PlaceboPart A: Dupilumab High DosePart A: Dupilumab Low Dose
Part A: Change From Baseline in Total Score as Measured by the Pediatric Eosinophilic Esophagitis Symptom Score (PEESS) Version 2.0 Caregiver Version (PEESSv2.0-C) at Week 16-11.83 ± 2.909-19.86 ± 2.577-10.10 ± 2.785
SecondaryPart A: Concentration of Functional Dupilumab in Serum at Baseline, Week 4 and 16

Concentration of functional dupilumab in serum at Baseline, Week 4 and 16 was reported in this outcome measure.

Time frame:
Baseline, Week 4 and 16
Reported as:
Mean · milligrams per liter (mg/L)
Part A: Concentration of Functional Dupilumab in Serum at Baseline, Week 4 and 16
milligrams per liter (mg/L)Part A: Dupilumab High DosePart A: Dupilumab Low Dose
Baseline0 ± 00 ± 0
Week 475.7 ± 25.740.6 ± 11.2
Week 16163 ± 60.886.0 ± 29.2
SecondaryPart B: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eosinophils/High Power Field at Week 52

Peak esophageal intraepithelial eosinophil count was measured from esophageal biopsies. A total of at least 9 mucosal pinch biopsies were collected from 3 esophageal regions: 3 proximal, 3 mid, and 3 distal. The peak esophageal intraepithelial eosinophil count at each visit was the maximum of the quantities of eosinophils in the most inflamed hpfs across the 3 regions. If the quantity of eosinophils was missing for 1 or 2 esophageal regions, the peak eosinophil count was the maximum of the quantities of eosinophils from the region(s) where eosinophil quantities were available.

Time frame:
At Week 52
Reported as:
Number · percentage of participants
Part B: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eosinophils/High Power Field at Week 52
percentage of participantsPart B: Placebo to Dupilumab Low DosePart B: Placebo to Dupilumab High DosePart B: Dupilumab Low Dose to Dupilumab Low DosePart B: Dupilumab High Dose to Dupilumab High Dose
Part B: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eosinophils/High Power Field at Week 5292.952.965.562.9
SecondaryPart B: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eosinophils/High Power Field at Week 52

Peak esophageal intraepithelial eosinophil count was measured from esophageal biopsies. A total of at least 9 mucosal pinch biopsies were collected from 3 esophageal regions: 3 proximal, 3 mid, and 3 distal. The peak esophageal intraepithelial eosinophil count at each visit was the maximum of the quantities of eosinophils in the most inflamed hpfs across the 3 regions. If the quantity of eosinophils was missing for 1 or 2 esophageal regions, the peak eosinophil count was the maximum of the quantities of eosinophils from the region(s) where eosinophil quantities were available.

Time frame:
At Week 52
Reported as:
Number · percentage of participants
Part B: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eosinophils/High Power Field at Week 52
percentage of participantsPart B: Placebo to Dupilumab Low DosePart B: Placebo to Dupilumab High DosePart B: Dupilumab Low Dose to Dupilumab Low DosePart B: Dupilumab High Dose to Dupilumab High Dose
Part B: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eosinophils/High Power Field at Week 5292.964.769.085.7
SecondaryPart B: Percent Change From Baseline in Peak Esophageal Intraepithelial Eosinophil Count at Week 52

Peak esophageal intraepithelial eosinophil count was measured from esophageal biopsies. A total of at least 9 mucosal pinch biopsies were collected from 3 esophageal regions: 3 proximal, 3 mid, and 3 distal. The peak esophageal intraepithelial eosinophil count at each visit was the maximum of the quantities of eosinophils in the most inflamed hpfs across the 3 regions. If the quantity of eosinophils was missing for 1 or 2 esophageal regions, the peak eosinophil count was the maximum of the quantities of eosinophils from the region(s) where eosinophil quantities were available.

Time frame:
Baseline, Week 52
Reported as:
Mean · percent change
Part B: Percent Change From Baseline in Peak Esophageal Intraepithelial Eosinophil Count at Week 52
percent changePart B: Placebo to Dupilumab Low DosePart B: Placebo to Dupilumab High DosePart B: Dupilumab Low Dose to Dupilumab Low DosePart B: Dupilumab High Dose to Dupilumab High Dose
Part B: Percent Change From Baseline in Peak Esophageal Intraepithelial Eosinophil Count at Week 52-92.72 ± 19.229-76.83 ± 41.228-85.41 ± 22.851-90.97 ± 14.482
SecondaryPart B: Change From Baseline in Mean Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) Grade Score at Week 52

EoE-HSS is a validated histologic scoring system that measures other histological abnormalities in addition to density of eosinophilic infiltration. Severity (grade) and extent (stage) of abnormalities will be scored using a 4-point scale (0 normal; 3 maximum change). Higher total score indicated greater severity \& extent of histological abnormalities. For each of 3 esophageal regions (proximal, mid, and distal), the ratio of the sum of assigned score for each evaluated feature divided by maximum possible score (maximum value is 24) was calculated. The mean grade scores summed over the 3 regions was the final score used in primary analysis, the mean grade score ranged from 0 to 3, with higher score indicating more severe.

Time frame:
Baseline, Week 52
Reported as:
Mean · Score on a scale
Part B: Change From Baseline in Mean Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) Grade Score at Week 52
Score on a scalePart B: Placebo to Dupilumab Low DosePart B: Placebo to Dupilumab High DosePart B: Dupilumab Low Dose to Dupilumab Low DosePart B: Dupilumab High Dose to Dupilumab High Dose
Part B: Change From Baseline in Mean Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) Grade Score at Week 52-0.804 ± 0.3099-0.885 ± 0.2962-0.773 ± 0.3374-0.967 ± 0.3920
SecondaryPart B: Change From Baseline in Mean Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) Stage Score at Week 52

EoE-HSS is a validated histologic scoring system that measures other histological abnormalities in addition to density of eosinophilic infiltration. Severity (grade) and extent (stage) of abnormalities will be scored using a 4-point scale (0 normal; 3 maximum change). Higher total score indicated greater severity \& extent of histological abnormalities. For each of 3 esophageal regions (proximal, mid, and distal), the ratio of the sum of assigned score for each evaluated feature divided by maximum possible score (maximum value is 24) was calculated. The mean stage scores summed over the 3 regions was the final score used in primary analysis, the mean stage score ranged from 0 to 3, with higher score indicating more severe.

Time frame:
Baseline, Week 52
Reported as:
Mean · Score on a scale
Part B: Change From Baseline in Mean Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) Stage Score at Week 52
Score on a scalePart B: Placebo to Dupilumab Low DosePart B: Placebo to Dupilumab High DosePart B: Dupilumab Low Dose to Dupilumab Low DosePart B: Dupilumab High Dose to Dupilumab High Dose
Part B: Change From Baseline in Mean Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) Stage Score at Week 52-0.767 ± 0.3114-0.855 ± 0.3485-0.784 ± 0.3183-0.892 ± 0.3181
SecondaryPart B: Absolute Change From Baseline in EoE Endoscopic Reference Total Score (EoE-EREFS) at Week 52

The EoE-EREFS is a validated endoscopic scoring system for inflammatory and remodeling features of EoE including edema, rings, exudates, furrows, and stricture. The score was assessed in the proximal and distal esophageal regions with each region scored from 0 to 9 with total scores possibly ranging from 0 to 18. Higher scores indicate worse endoscopic inflammatory and remodeling findings.

Time frame:
Baseline, Week 52
Reported as:
Mean · score on a scale
Part B: Absolute Change From Baseline in EoE Endoscopic Reference Total Score (EoE-EREFS) at Week 52
score on a scalePart B: Placebo to Dupilumab Low DosePart B: Placebo to Dupilumab High DosePart B: Dupilumab Low Dose to Dupilumab Low DosePart B: Dupilumab High Dose to Dupilumab High Dose
Part B: Absolute Change From Baseline in EoE Endoscopic Reference Total Score (EoE-EREFS) at Week 52-5.82 ± 1.722-3.64 ± 3.342-4.50 ± 3.203-4.77 ± 3.081
SecondaryPart B: Change From Baseline in the Proportion of Days With 1 or More EoE Signs Measured by Pediatric EoE Sign/Symptom Questionnaire - Caregiver Version (PESQ-C) at Week 52

PESQ-C is a novel, observer-reported outcome measure intended to be completed independently by caregivers of all pediatric EoE participants in the study.

Time frame:
Baseline, Week 52
Reported as:
Mean · proportion of days
Part B: Change From Baseline in the Proportion of Days With 1 or More EoE Signs Measured by Pediatric EoE Sign/Symptom Questionnaire - Caregiver Version (PESQ-C) at Week 52
proportion of daysPart B: Placebo to Dupilumab Low DosePart B: Placebo to Dupilumab High DosePart B: Dupilumab Low Dose to Dupilumab Low DosePart B: Dupilumab High Dose to Dupilumab High Dose
Part B: Change From Baseline in the Proportion of Days With 1 or More EoE Signs Measured by Pediatric EoE Sign/Symptom Questionnaire - Caregiver Version (PESQ-C) at Week 52-0.20 ± 0.373-0.47 ± 0.395-0.49 ± 0.339-0.30 ± 0.299
SecondaryPart B: Number of Sign-free Days During the 14-day Period Preceding Week 52 as Measured by the PESQ-C (for Participants Aged ≥1 to <12 Years)

PESQ-C is a novel, observer-reported outcome measure intended to be completed independently by caregivers of all pediatric EoE participants in the study.

Time frame:
Week 52
Reported as:
Mean · sign-free days
Part B: Number of Sign-free Days During the 14-day Period Preceding Week 52 as Measured by the PESQ-C (for Participants Aged ≥1 to <12 Years)
sign-free daysPart B: Placebo to Dupilumab Low DosePart B: Placebo to Dupilumab High DosePart B: Dupilumab Low Dose to Dupilumab Low DosePart B: Dupilumab High Dose to Dupilumab High Dose
Part B: Number of Sign-free Days During the 14-day Period Preceding Week 52 as Measured by the PESQ-C (for Participants Aged ≥1 to <12 Years)11.58 ± 3.96812.10 ± 4.65211.35 ± 3.94712.13 ± 4.053
SecondaryPart B: Change From Baseline in the Proportion of Total Segments Within a Day (Night, Morning, Afternoon, Evening) With 1 or More EoE Signs as Measured by the PESQ-C at Week 52

PESQ-C is a novel, observer-reported outcome measure intended to be completed independently by caregivers of all pediatric EoE participants in the study. The PESQ-C measured the occurrence of signs of EoE and was completed once daily via an electronic diary.

Time frame:
Baseline, Week 52
Reported as:
Mean · proportion of segments
Part B: Change From Baseline in the Proportion of Total Segments Within a Day (Night, Morning, Afternoon, Evening) With 1 or More EoE Signs as Measured by the PESQ-C at Week 52
proportion of segmentsPart B: Placebo to Dupilumab Low DosePart B: Placebo to Dupilumab High DosePart B: Dupilumab Low Dose to Dupilumab Low DosePart B: Dupilumab High Dose to Dupilumab High Dose
Part B: Change From Baseline in the Proportion of Total Segments Within a Day (Night, Morning, Afternoon, Evening) With 1 or More EoE Signs as Measured by the PESQ-C at Week 52-0.03 ± 0.249-0.24 ± 0.221-0.26 ± 0.250-0.17 ± 0.187
SecondaryPart B: Change From Baseline in the Proportion of Days With 1 or More EoE Signs by Pediatric EoE Sign/Symptom Questionnaire - Participant Version (PESQ-P) (for Participants Aged ≥8 to <12 Years) at Week 52

The PESQ-P was a participant-reported outcome measure intended to be completed independently by participants ≥8 to \<12 years of age. The PESQ-P measured occurrence of signs of EoE and was completed once daily via an electronic diary. Data from a 14-day period preceding the baseline visit and a 14-day period preceding week 16 will be used to calculate the proportion of days with 1 or more EoE symptoms.

Time frame:
Baseline, Week 52
Reported as:
Mean · proportion of days
Part B: Change From Baseline in the Proportion of Days With 1 or More EoE Signs by Pediatric EoE Sign/Symptom Questionnaire - Participant Version (PESQ-P) (for Participants Aged ≥8 to <12 Years) at Week 52
proportion of daysPart B: Placebo to Dupilumab Low DosePart B: Placebo to Dupilumab High DosePart B: Dupilumab Low Dose to Dupilumab Low DosePart B: Dupilumab High Dose to Dupilumab High Dose
Part B: Change From Baseline in the Proportion of Days With 1 or More EoE Signs by Pediatric EoE Sign/Symptom Questionnaire - Participant Version (PESQ-P) (for Participants Aged ≥8 to <12 Years) at Week 52-0.33 ± 0.322-0.43 ± 0.369-0.42 ± 0.400-0.26 ± 0.396
SecondaryPart B: Number of Symptom-free Days During the 14-day Period Preceding Week 52 as Measured by the PESQ-P (for Participants Aged ≥8 to <12 Years)

The PESQ-P was a participant-reported outcome measure intended to be completed independently by participants ≥8 to \<12 years of age. The PESQ-P measures the signs of EoE, including stomach pain, heartburn, acid reflux, regurgitation, vomiting, food refusal, and trouble swallowing food.

Time frame:
Week 52
Reported as:
Mean · sign-free days
Part B: Number of Symptom-free Days During the 14-day Period Preceding Week 52 as Measured by the PESQ-P (for Participants Aged ≥8 to <12 Years)
sign-free daysPart B: Placebo to Dupilumab Low DosePart B: Placebo to Dupilumab High DosePart B: Dupilumab Low Dose to Dupilumab Low DosePart B: Dupilumab High Dose to Dupilumab High Dose
Part B: Number of Symptom-free Days During the 14-day Period Preceding Week 52 as Measured by the PESQ-P (for Participants Aged ≥8 to <12 Years)9.33 ± 8.08311.67 ± 5.71510.64 ± 4.94313.63 ± 0.874
SecondaryPart B: Change From Baseline in the Proportion of Total Segments Within a Day (Night, Morning, Afternoon, Evening) With 1 or More EoE Signs as Measured by the PESQ-P (for Participants Aged ≥8 to <12 Years) at Week 52

The PESQ-P was a participant-reported outcome measure intended to be completed independently by EoE participants ≥8 to \<12 years of age. The PESQ-P measured the occurrence of signs of EoE and was completed once daily via an electronic diary. Data from a 14-day period preceding the baseline visit and a 14-day period preceding week 16 will be used to calculate the total time segments within a day (night, morning, afternoon, evening) with 1 or more EoE symptoms.

Time frame:
Baseline, Week 52
Reported as:
Mean · proportion of segments
Part B: Change From Baseline in the Proportion of Total Segments Within a Day (Night, Morning, Afternoon, Evening) With 1 or More EoE Signs as Measured by the PESQ-P (for Participants Aged ≥8 to <12 Years) at Week 52
proportion of segmentsPart B: Placebo to Dupilumab Low DosePart B: Placebo to Dupilumab High DosePart B: Dupilumab Low Dose to Dupilumab Low DosePart B: Dupilumab High Dose to Dupilumab High Dose
Part B: Change From Baseline in the Proportion of Total Segments Within a Day (Night, Morning, Afternoon, Evening) With 1 or More EoE Signs as Measured by the PESQ-P (for Participants Aged ≥8 to <12 Years) at Week 52-0.17 ± 0.164-0.26 ± 0.269-0.21 ± 0.293-0.16 ± 0.284
SecondaryPart B: Normalized Enrichment Score (NES) for the Relative Change From Baseline in the EoE Diagnostic Panel (EDP) at Week 52

A Normalized Enrichment Score (NES) is a way to generate a single numerical value to represent a complex gene expression signature. Changes in NES score represented the overall changes in the expression of that molecular phenotype. The NESs calculated for the EDP reflect the expression at post-baseline relative to Baseline of a gene set that is differentially expressed between esophageal biopsies from EoE participants compared to healthy controls as a way to evaluate normalization of the molecular pathology. For each subject, an NES of 0 indicates no change from baseline, a negative score shows a reduction in disease score (more like normal) and positive score shows worsening (more active disease). NES does not have minimum/maximum score.

Time frame:
Baseline, Week 52
Reported as:
Median · Score on a scale
Part B: Normalized Enrichment Score (NES) for the Relative Change From Baseline in the EoE Diagnostic Panel (EDP) at Week 52
Score on a scalePart B: Placebo to Dupilumab Low DosePart B: Placebo to Dupilumab High DosePart B: Dupilumab Low Dose to Dupilumab Low DosePart B: Dupilumab High Dose to Dupilumab High Dose
Part B: Normalized Enrichment Score (NES) for the Relative Change From Baseline in the EoE Diagnostic Panel (EDP) at Week 52-2.715 (-2.755 to -2.505)-2.615 (-2.810 to -2.430)-2.625 (-2.775 to -2.550)-2.670 (-2.710 to -2.530)
SecondaryPart B: Normalized Enrichment Score (NES) for the Relative Change From Baseline in the Type 2 Inflammation Signature (T2INF) at Week 52

A Normalized Enrichment Score (NES) is a way to generate a single numerical value to represent a complex gene expression signature. Changes in NES score represented the overall changes in the expression of that molecular phenotype. The NESs calculated for T2INF reflect the expression at post-baseline relative to Baseline of the pre-specified gene set as a way to evaluate normalization of type 2 inflammation with treatment. For each subject, an NES of 0 indicates no change from baseline, a negative score shows a reduction in disease score (more like normal) and positive score shows worsening (more active disease). NES does not have minimum/maximum score.

Time frame:
Baseline, Week 52
Reported as:
Median · Score on a scale
Part B: Normalized Enrichment Score (NES) for the Relative Change From Baseline in the Type 2 Inflammation Signature (T2INF) at Week 52
Score on a scalePart B: Placebo to Dupilumab Low DosePart B: Placebo to Dupilumab High DosePart B: Dupilumab Low Dose to Dupilumab Low DosePart B: Dupilumab High Dose to Dupilumab High Dose
Part B: Normalized Enrichment Score (NES) for the Relative Change From Baseline in the Type 2 Inflammation Signature (T2INF) at Week 52-1.960 (-2.000 to -1.895)-1.965 (-1.995 to -1.765)-1.920 (-1.965 to -1.865)-1.920 (-1.930 to -1.850)
SecondaryPart B: Change From Baseline in Body Weight for Age Percentile at Week 52

Body weight for age percentile was calculated based on the growth charts from the Centers for Disease Control and Prevention (CDC) for ages 0 to 20 years (for ages 2 to \<12 years) and World Health Organization (WHO) growth charts for ages 0 to \<2 years (for ages 1 to \<2 years). These charts included a set of smoothed percentiles along with CDC LMS (Lambda-Mu-Sigma) parameters to allow the calculation of percentiles.

Time frame:
Baseline, Week 52
Reported as:
Mean · Percentile
Part B: Change From Baseline in Body Weight for Age Percentile at Week 52
PercentilePart B: Placebo to Dupilumab Low DosePart B: Placebo to Dupilumab High DosePart B: Dupilumab Low Dose to Dupilumab Low DosePart B: Dupilumab High Dose to Dupilumab High Dose
Part B: Change From Baseline in Body Weight for Age Percentile at Week 52-0.02 ± 13.8935.48 ± 12.6444.75 ± 11.9685.96 ± 11.519
SecondaryPart B: Change From Baseline in Body Mass Index (BMI) for Age Z-score for Participants ≥2 Years of Age at Week 52

BMI for age z-score indicates how much higher or lower a participant's BMI for age is relative to a reference growth chart (based on the growth charts from Centers for Disease Control and Prevention \[CDC\] for ages 0 to 20 years \[for ages 2 to \<12 years\]). A z-score of "0" represents the population mean. An increase in the mean change in BMI for age z-score (ie, increase in the standard deviation \[SD\] from the reference growth chart) indicates an increase in BMI for age relative to the reference.

Time frame:
Baseline, Week 52
Reported as:
Mean · z-score
Part B: Change From Baseline in Body Mass Index (BMI) for Age Z-score for Participants ≥2 Years of Age at Week 52
z-scorePart B: Placebo to Dupilumab Low DosePart B: Placebo to Dupilumab High DosePart B: Dupilumab Low Dose to Dupilumab Low DosePart B: Dupilumab High Dose to Dupilumab High Dose
Part B: Change From Baseline in Body Mass Index (BMI) for Age Z-score for Participants ≥2 Years of Age at Week 52-0.0206 ± 0.546250.0687 ± 0.47605-0.0549 ± 0.885820.0987 ± 0.72329
SecondaryPart B: Change From Baseline in Weight for Age Z-score at Week 52

Weight for age z-score indicates how much higher or lower a participant's weight for age is relative to a reference growth chart (based on the growth charts from CDC for ages 0 to 20 years \[for ages 2 to \<12 years\] and World Health Organization (WHO) growth charts for ages 0 to \<2 years \[for ages 1 to \<2 years\]). A z-score of "0" represents the population mean. An increase in the mean change in weight for age z-score (increase in the SD from the reference growth chart) indicates an increase in weight for age relative to the reference.

Time frame:
Baseline, Week 52
Reported as:
Mean · z-score
Part B: Change From Baseline in Weight for Age Z-score at Week 52
z-scorePart B: Placebo to Dupilumab Low DosePart B: Placebo to Dupilumab High DosePart B: Dupilumab Low Dose to Dupilumab Low DosePart B: Dupilumab High Dose to Dupilumab High Dose
Part B: Change From Baseline in Weight for Age Z-score at Week 520.0640 ± 0.462640.2016 ± 0.394460.1445 ± 0.403100.2049 ± 0.40305
SecondaryPart B: Change From Baseline in Body Weight From Height Z-score at Week 52

Weight for height z-score indicates how much higher or lower a participant's weight for height is relative to a reference growth chart (based on the growth charts from CDC for ages 0 to 20 years \[for ages 2 to \<12 years\] and WHO growth charts for ages 0 to \<2 years \[for ages 1 to \<2 years\]). A z-score of "0" represents the population mean. An increase in the mean change in weight for height z-score (increase in the SD from the reference growth chart) indicates an increase in weight for height relative to the reference.

Time frame:
Baseline, Week 52
Reported as:
Mean · z-score
Part B: Change From Baseline in Body Weight From Height Z-score at Week 52
z-scorePart B: Placebo to Dupilumab Low DosePart B: Placebo to Dupilumab High DosePart B: Dupilumab Low Dose to Dupilumab Low DosePart B: Dupilumab High Dose to Dupilumab High Dose
Part B: Change From Baseline in Body Weight From Height Z-score at Week 520.0962 ± 0.48902-0.0100 ± 0.51706-0.2700 ± 1.04895-0.0151 ± 0.67968
SecondaryPart B: Concentration of Functional Dupilumab in Serum at Week 32 and 52

Concentration of functional dupilumab in serum at Week 32 and 52 was reported in this outcome measure.

Time frame:
Week 32 and 52
Reported as:
Mean · mg/L
Part B: Concentration of Functional Dupilumab in Serum at Week 32 and 52
mg/LPart B: Placebo to Dupilumab Low DosePart B: Placebo to Dupilumab High DosePart B: Dupilumab Low Dose to Dupilumab Low DosePart B: Dupilumab High Dose to Dupilumab High Dose
Week 32105 ± 49.8142 ± 48.599.0 ± 42.8186 ± 59.5
Week 52101 ± 44.3149 ± 59.183.0 ± 33.2179 ± 75.3
SecondaryPart A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Adverse Events of Special Interest (AESIs) and TEAEs Leading to Permanent Discontinuation of Study Drug

An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation patient administered with a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. A serious AE was any untoward medical occurrence that at any dose resulted in death, life-threatening, initial or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or a medically important event. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs include both Serious TEAEs and non-serious TEAEs. An AESI was defined as one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate.

Time frame:
From Baseline up to Week 16 in Part A
Reported as:
Count of participants · Participants
Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Adverse Events of Special Interest (AESIs) and TEAEs Leading to Permanent Discontinuation of Study Drug
ParticipantsPart A: Pooled PlaceboPart A: Dupilumab High DosePart A: Dupilumab Low Dose
Participants with any TEAE312726
Participants with any Serious TEAE021
Participants with any AESI121
Participants with any TEAE leading to permanent discontinuation of study drug200
SecondaryPart B: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Adverse Events of Special Interest (AESIs) and TEAEs Leading to Permanent Discontinuation of Study Drug

An AE was defined as any untoward medical occurrence in a participant or clinical investigation patient administered with a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. A serious AE was any untoward medical occurrence that at any dose resulted in death, life-threatening, initial or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or a medically important event. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs include both Serious TEAEs and non-serious TEAEs. An AESI was defined as one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate.

Time frame:
From Week 16 up to Week 52 in Part B
Reported as:
Count of participants · Participants
Part B: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Adverse Events of Special Interest (AESIs) and TEAEs Leading to Permanent Discontinuation of Study Drug
ParticipantsPart B: Placebo to Dupilumab Low DosePart B: Placebo to Dupilumab High DosePart B: Dupilumab Low Dose to Dupilumab Low DosePart B: Dupilumab High Dose to Dupilumab High Dose
Participants with any TEAE14152834
Participants with any Serious TEAE1032
Participants with any AESI0134
Participants with any TEAE leading to permanent discontinuation of study drug0001
SecondaryPart A: Number of Participants With Positive Treatment-emergent Antidrug Antibodies (ADA) Response

Treatment-emergent ADA was defined as a negative result or missing result at baseline with at least one positive post baseline result in the ADA assay. Samples positive in the dupilumab ADA assay were characterized for ADA titers (low, moderate and high). The low treatment-emergent ADA titer as defined as titer level \<1000, moderate as 1000 to 10000 and high as \>10000.

Time frame:
From Baseline up to Week 16 in Part A
Reported as:
Count of participants · Participants
Part A: Number of Participants With Positive Treatment-emergent Antidrug Antibodies (ADA) Response
ParticipantsPart A: Pooled PlaceboPart A: Dupilumab High DosePart A: Dupilumab Low Dose
Part A: Number of Participants With Positive Treatment-emergent Antidrug Antibodies (ADA) Response110
SecondaryPart A: Number of Participants With Positive Treatment-emergent Antidrug Antibodies (ADA) by Maximum Titer Category

Treatment-emergent ADA was defined as a negative result or missing result at baseline with at least one positive post baseline result in the ADA assay. Samples positive in the dupilumab ADA assay were characterized for ADA titers (low, moderate and high). The low treatment-emergent ADA titer as defined as titer level \<1000, moderate as 1000 to 10000 and high as \>10000.

Time frame:
From Baseline up to Week 16 in Part A
Reported as:
Count of participants · Participants
Part A: Number of Participants With Positive Treatment-emergent Antidrug Antibodies (ADA) by Maximum Titer Category
ParticipantsPart A: Pooled PlaceboPart A: Dupilumab High DosePart A: Dupilumab Low Dose
Treatment-emergent ADA Titer: Low110
Treatment-emergent ADA Titer: Moderate000
Treatment-emergent ADA Titer: High000
SecondaryPart B: Number of Participants With Positive Treatment-emergent Antidrug Antibodies (ADA) Response and Titer

Treatment-emergent ADA was defined as a negative result or missing result at baseline with at least one positive post baseline result in the ADA assay. Samples positive in the dupilumab ADA assay were characterized for ADA titers (low, moderate and high). The low treatment-emergent ADA titer as defined as titer level \<1000, moderate as 1000 to 10000 and high as \>10000. No participant exhibited a treatment-emergent ADA response in Part B and titer was not reported.

Time frame:
From Week 16 up to Week 52 in Part B
Reported as:
Count of participants · Participants
Part B: Number of Participants With Positive Treatment-emergent Antidrug Antibodies (ADA) Response and Titer
ParticipantsPart B: Placebo to Dupilumab Low DosePart B: Placebo to Dupilumab High DosePart B: Dupilumab Low Dose to Dupilumab Low DosePart B: Dupilumab High Dose to Dupilumab High Dose
Part B: Number of Participants With Positive Treatment-emergent Antidrug Antibodies (ADA) Response and Titer0000
SecondaryPart C: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eos/Hpf At Week 100
Time frame:
At Week 100
Reported as:
Number · Percentage of participants
Part C: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eos/Hpf At Week 100
Percentage of participantsPart C: Dupilumab
Part C: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eos/Hpf At Week 10092.7
SecondaryPart C: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eos/Hpf At Week 160
Time frame:
At Week 160

No measurements were reported for this outcome.

SecondaryPart C: Percent Change in Peak Esophageal Intraepithelial Eosinophil Count (Eos/Hpf) From Baseline to Week 100
Time frame:
Baseline to Week 100
Reported as:
Mean · Percentage of change
Part C: Percent Change in Peak Esophageal Intraepithelial Eosinophil Count (Eos/Hpf) From Baseline to Week 100
Percentage of changePart C: Dupilumab
Part C: Percent Change in Peak Esophageal Intraepithelial Eosinophil Count (Eos/Hpf) From Baseline to Week 100-91.50 ± 13.348
SecondaryPart C: Percent Change in Peak Esophageal Intraepithelial Eosinophil Count (Eos/Hpf) From Baseline to Week 160
Time frame:
Baseline to Week 160

No measurements were reported for this outcome.

SecondaryPart C: Absolute Change in Mean EoE-HSS From Baseline to Week 100
Time frame:
Baseline to Week 100
Reported as:
Mean · Score on a scale
Part C: Absolute Change in Mean EoE-HSS From Baseline to Week 100
Score on a scalePart C: Dupilumab
EoE-HSS Grade Score-0.851 ± 0.3909
EoE-HSS Stage Score-0.850 ± 0.3648
SecondaryPart C: Absolute Change in Mean EoE-HSS From Baseline to Week 160
Time frame:
Baseline to Week 160

No measurements were reported for this outcome.

SecondaryPart C: Absolute Change in EoE-EREFS From Baseline to Week 100
Time frame:
Baseline to Week 100
Reported as:
Mean · Score on a scale
Part C: Absolute Change in EoE-EREFS From Baseline to Week 100
Score on a scalePart C: Dupilumab
Part C: Absolute Change in EoE-EREFS From Baseline to Week 100-5.34 ± 2.535
SecondaryPart C: Absolute Change in EoE-EREFS From Baseline to Week 160
Time frame:
Baseline to Week 160

No measurements were reported for this outcome.

SecondaryPart C: Change in Total Score as Measured by the PEESSv2.0- Caregiver Version Questionnaire From Baseline to Week 100

The PEESSv2.0-C is a caregiver-reported outcome measure that assesses the frequency and severity of EoE symptoms among pediatric participants. The PEESSv2.0-C consists of 20 items and has a one-month recall period. Each item had a 0-4 scale, which was transformed to 0-100 as follows: 0 = 0, 1 = 25, 2 = 50, 3 = 75, 4 = 100. The mean total PEESSv2.0 score was computed as the sum of all the item scores over the number of items answered. The total PEESSv2.0-C score ranges from 0 to 100 where higher scores indicate greater symptom burden among pediatric EoE participants.

Time frame:
Baseline to Week 100
Reported as:
Mean · Score on a scale
Part C: Change in Total Score as Measured by the PEESSv2.0- Caregiver Version Questionnaire From Baseline to Week 100
Score on a scalePart C: Dupilumab
Part C: Change in Total Score as Measured by the PEESSv2.0- Caregiver Version Questionnaire From Baseline to Week 100-25.03 ± 21.867
SecondaryPart C: NES for the Relative Change in the EDP Transcriptome Signature From Baseline to Week 100

A Normalized Enrichment Score (NES) is a way to generate a single numerical value to represent a complex gene expression signature. Changes in NES score represented the overall changes in the expression of that molecular phenotype. The NESs calculated for the EDP reflect the expression at post-baseline relative to Baseline of a gene set that is differentially expressed between esophageal biopsies from EoE participants compared to healthy controls as a way to evaluate normalization of the molecular pathology. For each subject, an NES of 0 indicates no change from baseline, a negative score shows a reduction in disease score (more like normal) and positive score shows worsening (more active disease). NES does not have minimum/maximum score.

Time frame:
Baseline to Week 100
Reported as:
Median · Score on a scale
Part C: NES for the Relative Change in the EDP Transcriptome Signature From Baseline to Week 100
Score on a scalePart C: Dupilumab
Part C: NES for the Relative Change in the EDP Transcriptome Signature From Baseline to Week 100-2.720 (-2.800 to -2.510)
SecondaryPart C: NES for the Relative Change in the EDP Transcriptome Signature From Baseline to Week 160

A Normalized Enrichment Score (NES) is a way to generate a single numerical value to represent a complex gene expression signature. Changes in NES score represented the overall changes in the expression of that molecular phenotype. The NESs calculated for the EDP reflect the expression at post-baseline relative to Baseline of a gene set that is differentially expressed between esophageal biopsies from EoE participants compared to healthy controls as a way to evaluate normalization of the molecular pathology. For each subject, an NES of 0 indicates no change from baseline, a negative score shows a reduction in disease score (more like normal) and positive score shows worsening (more active disease). NES does not have minimum/maximum score.

Time frame:
Baseline to Week 160

No measurements were reported for this outcome.

SecondaryPart C: NES for the Relative Change in the Type 2 Inflammation Transcriptome Signature Baseline to Week 100
Time frame:
Baseline to Week 100
Reported as:
Median · Score on a scale
Part C: NES for the Relative Change in the Type 2 Inflammation Transcriptome Signature Baseline to Week 100
Score on a scalePart C: Dupilumab
Part C: NES for the Relative Change in the Type 2 Inflammation Transcriptome Signature Baseline to Week 100-1.970 (-2.000 to -1.900)
SecondaryPart C: NES for the Relative Change in the Type 2 Inflammation Transcriptome Signature From Baseline to Week 160
Time frame:
Baseline to Week 160

No measurements were reported for this outcome.

SecondaryPart C: Change in Body Weight for Age Percentile From Baseline up to Week 100

Body weight for age percentile was calculated based on the growth charts from the Centers for Disease Control and Prevention (CDC) for ages 0 to 20 years (for ages 2 to \<12 years) and World Health Organization (WHO) growth charts for ages 0 to \<2 years (for ages 1 to \<2 years). These charts included a set of smoothed percentiles along with CDC LMS (Lambda-Mu-Sigma) parameters to allow the calculation of percentiles.

Time frame:
Baseline up to Week 100
Reported as:
Mean · Percentile
Part C: Change in Body Weight for Age Percentile From Baseline up to Week 100
PercentilePart C: Dupilumab
Part C: Change in Body Weight for Age Percentile From Baseline up to Week 10010.63 ± 18.227
SecondaryPart C: Change in Body Mass Index for Age Z-score From Baseline up to Week 100

Difference in the 100-week change from baseline in BMI-for-age Z-score. BMI-for-age Z-scores are based on a reference growth chart (based on the growth charts from Centers for Disease Control and Prevention \[CDC\] for ages 0 to 20 years \[for ages 2 to \<12 years\]. A z-score of "0" represents the population mean. The Z-score indicates the number of standard deviations away from the mean of the reference population. A negative Z-score indicates values lower than the population mean while a positive Z-score indicates values higher than the population mean.

Time frame:
Baseline up to Week 100
Reported as:
Mean · z-score
Part C: Change in Body Mass Index for Age Z-score From Baseline up to Week 100
z-scorePart C: Dupilumab
Part C: Change in Body Mass Index for Age Z-score From Baseline up to Week 1000.2009 ± 0.67389
SecondaryPart C: Change in Weight for Age Z-score From Baseline up to Week 100

Difference in the 100-week change from baseline in weight-for-age Z-score. Weight-for-age Z-scores are based on a reference growth chart (based on the growth charts from Centers for Disease Control and Prevention \[CDC\] for ages 0 to 20 years \[for ages 2 to \<12 years\]. A z-score of "0" represents the population mean. The Z-score indicates the number of standard deviations away from the mean of the reference population. A negative Z-score indicates values lower than the population mean while a positive Z-score indicates values higher than the population mean.

Time frame:
Baseline up to Week 100
Reported as:
Mean · z-score
Part C: Change in Weight for Age Z-score From Baseline up to Week 100
z-scorePart C: Dupilumab
Part C: Change in Weight for Age Z-score From Baseline up to Week 1000.3376 ± 0.59272
SecondaryPart C: Change in Weight for Age Z-score From Baseline up to Week 160

Weight for age z-score indicates how much higher or lower a participant's weight for age is relative to a reference growth chart (based on the growth charts from CDC for ages 0 to 20 years \[for ages 2 to \<12 years\] and World Health Organization (WHO) growth charts for ages 0 to \<2 years \[for ages 1 to \<2 years\]). An increase in the mean change in weight for age z-score (increase in the SD from the reference growth chart) indicates an increase in weight for age relative to the reference.

Time frame:
Baseline up to Week 160

No measurements were reported for this outcome.

SecondaryPart C: Change in Weight for Height Z-score From Baseline up to Week 100

Difference in the 100-week change from baseline in Weight for height Z-score. Weight for height Z-scores are based on a reference growth chart (based on the growth charts from Centers for Disease Control and Prevention \[CDC\] for ages 0 to 20 years \[for ages 2 to \<12 years\]. A z-score of "0" represents the population mean. The Z-score indicates the number of standard deviations away from the mean of the reference population. A negative Z-score indicates values lower than the population mean while a positive Z-score indicates values higher than the population mean.

Time frame:
Baseline up to Week 100
Reported as:
Mean · z-score
Part C: Change in Weight for Height Z-score From Baseline up to Week 100
z-scorePart C: Dupilumab
Part C: Change in Weight for Height Z-score From Baseline up to Week 1000.3301 ± 0.84791
SecondaryPart C: Change in Weight for Height Z-score From Baseline up to Week 160

Weight for height z-score indicates how much higher or lower a participant's weight for height is relative to a reference growth chart (based on the growth charts from CDC for ages 0 to 20 years \[for ages 2 to \<12 years\] and WHO growth charts for ages 0 to \<2 years \[for ages 1 to \<2 years\]). An increase in the mean change in weight for height z-score (increase in the SD from the reference growth chart) indicates an increase in weight for height relative to the reference.

Time frame:
Baseline up to Week 160

No measurements were reported for this outcome.

SecondaryPart C: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eos/Hpf (400×) at Week 100
Time frame:
At Week 100
Reported as:
Number · Percentage of participants
Part C: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eos/Hpf (400×) at Week 100
Percentage of participantsPart C: Dupilumab
Part C: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eos/Hpf (400×) at Week 10070.7
SecondaryPart C: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eos/Hpf (400×) at Week 160
Time frame:
At Week 160

No measurements were reported for this outcome.

SecondaryPart C: Percentage of Participants (With Food Elimination Diet Regimens at Baseline) That Have a Re-introduction of a Previously Eliminated Food Group From Baseline up to Week 100
Time frame:
Baseline up to Week 100
Reported as:
Number · Percentage of participants
Part C: Percentage of Participants (With Food Elimination Diet Regimens at Baseline) That Have a Re-introduction of a Previously Eliminated Food Group From Baseline up to Week 100
Percentage of participantsPart C: Dupilumab
Part C: Percentage of Participants (With Food Elimination Diet Regimens at Baseline) That Have a Re-introduction of a Previously Eliminated Food Group From Baseline up to Week 10014.8
SecondaryPart C: Percentage of Participants (With Food Elimination Diet Regimens at Baseline) That Have a Re-introduction of a Previously Eliminated Food Group From Baseline up to Week 160
Time frame:
Baseline up to Week 160

No measurements were reported for this outcome.

SecondaryPart C: Number of Participants With TEAEs
Time frame:
Up to Week 152
Reported as:
Count of participants · Participants
Part C: Number of Participants With TEAEs
ParticipantsPart C: Dupilumab
Part C: Number of Participants With TEAEs53
SecondaryPart C: Number of Participants With Treatment-emergent SAEs
Time frame:
Up to Week 152
Reported as:
Count of participants · Participants
Part C: Number of Participants With Treatment-emergent SAEs
ParticipantsPart C: Dupilumab
Part C: Number of Participants With Treatment-emergent SAEs3
SecondaryPart C: Number of Participants With Treatment-emergent AESIs
Time frame:
Up to Week 152
Reported as:
Count of participants · Participants
Part C: Number of Participants With Treatment-emergent AESIs
ParticipantsPart C: Dupilumab
Part C: Number of Participants With Treatment-emergent AESIs6
SecondaryPart C: Number of Participants With TEAEs Leading to Permanent Discontinuation of Study Treatment
Time frame:
Up to Week 152
Reported as:
Count of participants · Participants
Part C: Number of Participants With TEAEs Leading to Permanent Discontinuation of Study Treatment
ParticipantsPart C: Dupilumab
Part C: Number of Participants With TEAEs Leading to Permanent Discontinuation of Study Treatment0
SecondaryPart C: Number of Participants With Treatment-emergent ADA Responses
Time frame:
From Week 52 up to Week 152
Reported as:
Number · Participants
Part C: Number of Participants With Treatment-emergent ADA Responses
ParticipantsPart C: Dupilumab
Part C: Number of Participants With Treatment-emergent ADA Responses0
SecondaryPart C: Concentration of Functional Dupilumab in Serum at Week 100
Time frame:
At Week 100
Reported as:
Mean · mg/L
Part C: Concentration of Functional Dupilumab in Serum at Week 100
mg/LPart C: Dupilumab
Part C: Concentration of Functional Dupilumab in Serum at Week 100180 ± 96.9

Adverse events

Collected over From signing of the informed consent up to week 152.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Pooled Placebo (Placebo)0/34 (0%)0/34 (0%)28/34 (82.4%)
Part A: Dupilumab Low Dose0/30 (0%)0/30 (0%)24/30 (80%)
Part A: Dupilumab High Dose0/37 (0%)2/37 (5.4%)26/37 (70.3%)
Part B: Placebo to Dupilumab Low Dos0/14 (0%)1/14 (7.1%)14/14 (100%)
Part B: Placebo to Dupilumab High Dose0/18 (0%)0/18 (0%)16/18 (88.9%)
Part B: Dupilumab Low Dose to Dupilumab Low Dose0/29 (0%)2/29 (6.9%)27/29 (93.1%)
Part B: Dupilumab High Dose to Dupilumab High Dose0/37 (0%)2/37 (5.4%)31/37 (83.8%)
Part C: Dupilumab0/61 (0%)3/61 (4.9%)48/61 (78.7%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventPart A: Pooled Placebo (Placebo)Part A: Dupilumab Low DosePart A: Dupilumab High DosePart B: Placebo to Dupilumab Low DosPart B: Placebo to Dupilumab High DosePart B: Dupilumab Low Dose to Dupilumab Low DosePart B: Dupilumab High Dose to Dupilumab High DosePart C: Dupilumab
LeukocytosisBlood and lymphatic system disorders0/340/300/371/140/180/290/370/61
PyrexiaGeneral disorders0/340/300/371/140/180/290/370/61
HCoV-OC43 infectionInfections and infestations0/340/300/370/140/181/290/370/61
Throat tightnessRespiratory, thoracic and mediastinal disorders0/340/300/370/140/181/290/370/61
Procedural painInjury, poisoning and procedural complications0/340/301/370/140/180/290/370/61
NephrolithiasisRenal and urinary disorders0/340/301/370/140/180/290/370/61
Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders0/340/300/370/140/180/291/370/61
Post procedural haemorrhageInjury, poisoning and procedural complications0/340/300/370/140/180/291/370/61
AsthmaRespiratory, thoracic and mediastinal disorders0/340/300/370/140/180/291/370/61
Obstructive sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders0/340/301/370/140/180/290/370/61
Most frequent other events
Showing 10 of 123
Most frequent other events
EventPart A: Pooled Placebo (Placebo)Part A: Dupilumab Low DosePart A: Dupilumab High DosePart B: Placebo to Dupilumab Low DosPart B: Placebo to Dupilumab High DosePart B: Dupilumab Low Dose to Dupilumab Low DosePart B: Dupilumab High Dose to Dupilumab High DosePart C: Dupilumab
COVID-19Infections and infestations0/349/306/373/146/187/2911/375/61
Injection site reactionGeneral disorders7/344/304/374/145/184/295/375/61
InfluenzaInfections and infestations0/340/301/374/141/184/294/373/61
CoughRespiratory, thoracic and mediastinal disorders2/342/301/371/145/184/295/378/61
Upper respiratory tract infectionInfections and infestations3/341/300/372/141/188/292/378/61
HeadacheNervous system disorders1/344/302/370/144/183/294/376/61
PyrexiaGeneral disorders1/340/302/373/142/183/296/3711/61
Injection site painGeneral disorders0/343/300/373/141/181/291/373/61
UrticariaSkin and subcutaneous tissue disorders2/342/301/373/140/182/291/372/61
Pharyngitis streptococcalInfections and infestations0/340/300/372/141/182/290/3713/61

Baseline characteristics

Analysis was performed on Part A full analysis set (FAS) which included all randomized participants in Part A.

Age, Continuous
Age, Continuous(years)Part A: Pooled PlaceboPart A: Dupilumab Low DosePart A: Dupilumab High DoseTotal
Mean7.2 ± 3.037.2 ± 3.076.8 ± 3.117.1 ± 3.05
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Pooled PlaceboPart A: Dupilumab Low DosePart A: Dupilumab High DoseTotal
Female96924
Male25252878
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: Pooled PlaceboPart A: Dupilumab Low DosePart A: Dupilumab High DoseTotal
Hispanic or Latino3227
Not Hispanic or Latino30293392
Unknown or Not Reported1023
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: Pooled PlaceboPart A: Dupilumab Low DosePart A: Dupilumab High DoseTotal
White30223284
Black or African American34411
Asian0112
Other1405
08

Study locations

27 sites
  • Regeneron Study Site
    Phoenix, Arizona 85016, United States
  • Regeneron Study Site
    Little Rock, Arkansas 72202, United States
  • Regeneron Study Site
    Los Angeles, California 90027, United States
  • Regeneron Study Site
    San Francisco, California 94143, United States
  • Regeneron Study Site
    Aurora, Colorado 80045, United States
  • Regeneron Study Site
    St. Petersburg, Florida 33701, United States
  • Regeneron Study Site
    Atlanta, Georgia 30322, United States
  • Regeneron Study Site
    Atlanta, Georgia 30342, United States
  • Regeneron Study Site
    Chicago, Illinois 60611, United States
  • Regeneron Study Site
    Indianapolis, Indiana 46202, United States
  • Regeneron Study Site
    Iowa City, Iowa 52242, United States
  • Regeneron Study Site
    Boston, Massachusetts 02111, United States
  • Regeneron Study Site
    Boston, Massachusetts 02114, United States
  • Regeneron Study Site
    Boston, Massachusetts 02115, United States
  • Regeneron Study Site
    Lincoln, Nebraska 68510, United States
  • Regeneron Study Site
    New York, New York 10029, United States
  • Regeneron Study Site
    New York, New York 10032, United States
  • Regeneron Study Site
    New York, New York 10065, United States
  • Regeneron Study Site
    Chapel Hill, North Carolina 27599, United States
  • Regeneron Study Site
    Cincinnati, Ohio 45229, United States
  • Regeneron Study Site
    Cleveland, Ohio 44106, United States
  • Regeneron Study Site
    Philadelphia, Pennsylvania 19104, United States
  • Regeneron Study Site
    Dallas, Texas 75207, United States
  • Regeneron Study Site
    Fort Worth, Texas 76104, United States
  • Regeneron Study Site
    Houston, Texas 77030, United States
  • Regeneron Study Site
    Milwaukee, Wisconsin 53226, United States
  • Regeneron Study Site
    London, Ontario N6A 5W9, Canada
09

References and documents

Publications

  • Lim WK, Wipperman MF, Rothenberg ME, Collins MH, Hamon SC, Chehade M, Spergel JM, Gayvert KM, Ehmann PJ, Horowitz JE, Farrell AB, Dellon ES, Maloney J, Radin A, Louisias M, Wolfe K, Akinlade B, Ajithdoss DK, Herman G, Yancopoulos GD, Hamilton JD. Dupilumab normalizes the eosinophilic esophagitis disease transcriptome. J Allergy Clin Immunol. 2026 Apr 22:S0091-6749(26)00263-0. doi: 10.1016/j.jaci.2026.01.033. Online ahead of print. PubMed 42031097 ↗
  • Nguyen JH, Chehade M, Dellon ES, Radin A, Chittenden J, Kamal MA, Louisias M, Xu C, Kosloski MP. Population Pharmacokinetics of Dupilumab in Adults, Adolescents, and Children With Eosinophilic Esophagitis. Clin Pharmacol Ther. 2026 Jun;119(6):1555-1564. doi: 10.1002/cpt.70233. Epub 2026 Feb 26. PubMed 41749054 ↗
  • Chehade M, McCann E, Spergel J, Yaworsky A, Lamoureux RE, Litcher-Kelly L, Burbridge C, Sutter C, Newton L, Liu R, Tilton ST, Kamat S, Dellon ES. Validation of the Novel Pediatric Eosinophilic Esophagitis Sign/Symptom Questionnaire-Caregiver Version in EoE KIDS. J Allergy Clin Immunol Pract. 2026 Apr;14(4):899-906. doi: 10.1016/j.jaip.2026.01.001. Epub 2026 Jan 12. PubMed 41534558 ↗
  • Chehade M, Dellon ES, Spergel JM, Collins MH, Rothenberg ME, Pesek RD, Hirano I, Liu R, Laws E, Mortensen E, Martincova R, Shabbir A, McCann E, Kamal MA, Kosloski MP, Hamilton JD, Samuely C, Lim WK, Wipperman MF, Farrell A, Patel N, Yancopoulos GD, Glotfelty L, Maloney J. Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age. N Engl J Med. 2024 Jun 27;390(24):2239-2251. doi: 10.1056/NEJMoa2312282. PubMed 38924731 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All Individual Patient Data that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.

Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Jun 2022, 21 months.

Results were first posted in Aug 2024, 2 years 2 months after primary completion. A results delay was requested in Jun 2023.

Of 16 phase 3 interventional studies under Eosinophilic Esophagitis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 37. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2020
First posted
May 19, 2020
StartActual
Sep 1, 2020
Primary completionActual
Jun 2, 2022
CompletionActual
May 14, 2024
Results delay requested
Jun 1, 2023
Results first posted
Aug 27, 2024
Last update
Oct 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04394351
Collaborators
Sanofi
Responsible party
Sponsor
First posted
May 19, 2020
Start date
Sep 1, 2020
Primary completion
Jun 2, 2022
Completion
May 14, 2024
Results posted
Aug 27, 2024
Last update
Oct 27, 2025

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion